ATE509102T1 - Immunomodulatorische oligonukleotide - Google Patents

Immunomodulatorische oligonukleotide

Info

Publication number: ATE509102T1
Authority: AT; Austria
Prior art keywords: immunomodulatory oligonucleotides; oligonucleotides; immunomodulatory; stabilised; contain
Prior art date: 1994-07-15

Application number

AT01202813T

Other languages

English (en)

Inventor

Arthur Krieg

Dennis Klinman

Alfred Steinberg

Original Assignee

Univ Iowa Res Found

Us Health

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-07-15

Filing date

1995-02-07

Publication date

2011-05-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23056334&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE509102(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1995-02-07 Application filed by Univ Iowa Res Found, Us Health filed Critical Univ Iowa Res Found

2011-05-15 Application granted granted Critical

2011-05-15 Publication of ATE509102T1 publication Critical patent/ATE509102T1/de

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/17—Immunomodulatory nucleic acids
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Molecular Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Biotechnology (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Biomedical Technology (AREA)
Oncology (AREA)
Microbiology (AREA)
Virology (AREA)
General Engineering & Computer Science (AREA)
Communicable Diseases (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Physics & Mathematics (AREA)
Biophysics (AREA)
Tropical Medicine & Parasitology (AREA)
Analytical Chemistry (AREA)
Mycology (AREA)
Dermatology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Plant Pathology (AREA)
Pain & Pain Management (AREA)

AT01202813T 1994-07-15 1995-02-07 Immunomodulatorische oligonukleotide ATE509102T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US27635894A	1994-07-15	1994-07-15

Publications (1)

Publication Number	Publication Date
ATE509102T1 true ATE509102T1 (de)	2011-05-15

Family

ID=23056334

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
AT95911630T ATE328890T1 (de)	1994-07-15	1995-02-07	Immunomodulatorische oligonukleotide
AT01202811T ATE420171T1 (de)	1994-07-15	1995-02-07	Immunomodulatorische oligonukleotide
AT01202813T ATE509102T1 (de)	1994-07-15	1995-02-07	Immunomodulatorische oligonukleotide

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
AT95911630T ATE328890T1 (de)	1994-07-15	1995-02-07	Immunomodulatorische oligonukleotide
AT01202811T ATE420171T1 (de)	1994-07-15	1995-02-07	Immunomodulatorische oligonukleotide

Country Status (12)

Country	Link
US (1)	US6194388B1 (de)
EP (4)	EP1167379A3 (de)
JP (7)	JP3468773B2 (de)
AT (3)	ATE328890T1 (de)
AU (1)	AU713040B2 (de)
CA (2)	CA2560114A1 (de)
DE (2)	DE69535905D1 (de)
DK (1)	DK0772619T4 (de)
ES (3)	ES2320315T5 (de)
HK (3)	HK1043598A1 (de)
PT (1)	PT772619E (de)
WO (1)	WO1996002555A1 (de)

Families Citing this family (864)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5849719A (en)	1993-08-26	1998-12-15	The Regents Of The University Of California	Method for treating allergic lung disease
US6727230B1 (en) *	1994-03-25	2004-04-27	Coley Pharmaceutical Group, Inc.	Immune stimulation by phosphorothioate oligonucleotide analogs
US6239116B1 (en)	1994-07-15	2001-05-29	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US6429199B1 (en) *	1994-07-15	2002-08-06	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules for activating dendritic cells
US20030026782A1 (en) *	1995-02-07	2003-02-06	Arthur M. Krieg	Immunomodulatory oligonucleotides
US6207646B1 (en) *	1994-07-15	2001-03-27	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US7935675B1 (en)	1994-07-15	2011-05-03	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
WO1996002555A1 (en) *	1994-07-15	1996-02-01	The University Of Iowa Research Foundation	Immunomodulatory oligonucleotides
US5981501A (en) *	1995-06-07	1999-11-09	Inex Pharmaceuticals Corp.	Methods for encapsulating plasmids in lipid bilayers
US7422902B1 (en) *	1995-06-07	2008-09-09	The University Of British Columbia	Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
WO1997025429A1 (en)	1996-01-04	1997-07-17	Rican Limited	Helicobacter pylori bacterioferritin
ATE437943T1 (de) *	1996-01-30	2009-08-15	Univ California	Expressionsvektoren, die eine antigen-spezifische immunantwort induzieren, und methoden für ihre verwendung.
FR2750704B1 (fr)	1996-07-04	1998-09-25	Rhone Poulenc Rorer Sa	Procede de production d'adn therapeutique
US5856462A (en) *	1996-09-10	1999-01-05	Hybridon Incorporated	Oligonucleotides having modified CpG dinucleosides
AU768178B2 (en) *	1996-10-11	2003-12-04	Regents Of The University Of California, The	Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
AU4992197A (en)	1996-10-11	1998-05-11	Regents Of The University Of California, The	Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
EP0855184A1 (de) *	1997-01-23	1998-07-29	Grayson B. Dr. Lipford	Pharmazeutisches Präparat das ein Polynukleotid und ein Antigen enthält, insbesondere zur Impfung
AU738513B2 (en) *	1997-02-28	2001-09-20	University Of Iowa Research Foundation, The	Use of nucleic acids containing unmethylated CpG dinucleotide in the treatment of LPS-associated disorders
DE69841122D1 (de) *	1997-03-10	2009-10-15	Coley Pharm Gmbh	Verwendung von nicht-methyliertem CpG Dinukleotid in Kombination mit Aluminium als Adjuvantien
US6406705B1 (en)	1997-03-10	2002-06-18	University Of Iowa Research Foundation	Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6426334B1 (en)	1997-04-30	2002-07-30	Hybridon, Inc.	Oligonucleotide mediated specific cytokine induction and reduction of tumor growth in a mammal
WO1998051278A2 (en)	1997-05-14	1998-11-19	Inex Pharmaceuticals Corporation	High efficiency encapsulation of charged therapeutic agents in lipid vesicles
US20030104044A1 (en) *	1997-05-14	2003-06-05	Semple Sean C.	Compositions for stimulating cytokine secretion and inducing an immune response
EP0983289A4 (de) *	1997-05-19	2001-04-25	Merck & Co Inc	Oligonukleotidhilfsmittel
US6339068B1 (en)	1997-05-20	2002-01-15	University Of Iowa Research Foundation	Vectors and methods for immunization or therapeutic protocols
US6589940B1 (en)	1997-06-06	2003-07-08	Dynavax Technologies Corporation	Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
EP1374894A3 (de) *	1997-06-06	2004-09-22	Dynavax Technologies Corporation	Immunstimulierende Oligonukleotide, Zusammensetzungen und Verwendungen davon
US20040006034A1 (en) *	1998-06-05	2004-01-08	Eyal Raz	Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
JP4280309B2 (ja) *	1997-06-06	2009-06-17	ザリージェンツオブザユニバーシティーオブカリフォルニア	Ｄｎａ免疫刺激配列活性の阻害剤
ATE353657T1 (de) *	1997-09-05	2007-03-15	Univ California	Verwendung von immunerregenden oligonukleotiden zur vorbeugung oder behandlung von asthma
GB9724531D0 (en)	1997-11-19	1998-01-21	Smithkline Biolog	Novel compounds
DK1584685T3 (da)	1998-02-05	2011-07-11	Glaxosmithkline Biolog Sa	Tumorassocieret antigenderivater fra Mage-familien, anvendt til fremstilling af fusionsproteiner med T-hjælper epitoper og sammensætninger til vaccination
US20020147143A1 (en)	1998-03-18	2002-10-10	Corixa Corporation	Compositions and methods for the therapy and diagnosis of lung cancer
DE69935507T2 (de)	1998-04-03	2007-12-06	University Of Iowa Research Foundation	Verfahren und produkte zur stimulierung des immunsystems mittels immunotherapeutischer oligonukleotide und zytokine
KR20010042573A (ko) *	1998-04-09	2001-05-25	장 스테판느	애쥬번트 조성물
GB9808866D0 (en)	1998-04-24	1998-06-24	Smithkline Beecham Biolog	Novel compounds
EP1077708A1 (de) *	1998-05-06	2001-02-28	University Of Iowa Research Foundation	Methoden zur preventiven und therapeutischen behandlung von parasitären infektionen und damit verbundener krankheiten mittels cpg oligonukleotiden
AU760795B2 (en) *	1998-05-14	2003-05-22	Coley Pharmaceutical Gmbh	Methods for regulating hematopoiesis using CpG-oligonucleotides
CA2330916C (en)	1998-05-19	2011-04-05	Research Development Foundation	Triterpene compositions and methods for use thereof
AU761899B2 (en) *	1998-05-22	2003-06-12	Ottawa Health Research Institute	Methods and products for inducing mucosal immunity
US6881561B1 (en)	1998-05-27	2005-04-19	Cheil Jedang Corporation	Endonuclease of immune cell, process for producing the same and immune adjuvant using the same
KR19990086271A (ko) *	1998-05-27	1999-12-15	손경식	면역세포의 신규한 엔도뉴클레아제 및 이를 사용한 면역보조제
US6562798B1 (en)	1998-06-05	2003-05-13	Dynavax Technologies Corp.	Immunostimulatory oligonucleotides with modified bases and methods of use thereof
US20030022854A1 (en)	1998-06-25	2003-01-30	Dow Steven W.	Vaccines using nucleic acid-lipid complexes
US6693086B1 (en) *	1998-06-25	2004-02-17	National Jewish Medical And Research Center	Systemic immune activation method using nucleic acid-lipid complexes
US20040247662A1 (en) *	1998-06-25	2004-12-09	Dow Steven W.	Systemic immune activation method using nucleic acid-lipid complexes
EP1100807A1 (de) *	1998-07-27	2001-05-23	University Of Iowa Research Foundation	Stereoisomere von cpg oligonukleotiden und verwandte verfahren
BRPI9912663B8 (pt)	1998-07-31	2021-07-06	Int Inst Cancer Immunology Inc	vacina contra cáncer e polipeptìdeo.
BR9912671A (pt)	1998-08-07	2001-05-02	Univ Washington	Antìgenos imunológicos para o vìrus de herpes simples e métodos para sua utilização
CA2340174C (en) *	1998-08-10	2011-01-04	Aquila Biopharmaceuticals, Inc.	Compositions of cpg and saponin adjuvants and methods thereof
JP2002524473A (ja) *	1998-09-09	2002-08-06	ジエンザイムコーポレイション	プラスミドベクターのメチル化
US6692752B1 (en)	1999-09-08	2004-02-17	Smithkline Beecham Biologicals S.A.	Methods of treating human females susceptible to HSV infection
FR2783170B1 (fr) *	1998-09-11	2004-07-16	Pasteur Merieux Serums Vacc	Emulsion immunostimulante
ES2259478T3 (es) *	1998-09-18	2006-10-01	Dynavax Technologies Corporation	Metodos para tratar trastornos asociados con la ige y composiciones para este uso.
US20030235557A1 (en)	1998-09-30	2003-12-25	Corixa Corporation	Compositions and methods for WT1 specific immunotherapy
CA2346452A1 (en) *	1998-10-05	2000-04-13	The Regents Of The University Of California	Methods and adjuvants for stimulating mucosal immunity
DK1126876T3 (da)	1998-10-16	2007-07-02	Glaxosmithkline Biolog Sa	Adjuvanssystemer og vacciner
EP2277892A3 (de)	1998-12-08	2011-04-27	Corixa Corporation	Verbindungen und Verfahren zur Behandlung und Diagnose von Chlamydia-Infektionen
EP2374889A3 (de)	1998-12-08	2012-02-22	GlaxoSmithKline Biologicals SA	Neue Verbindungen
US20020119158A1 (en)	1998-12-17	2002-08-29	Corixa Corporation	Compositions and methods for the therapy and diagnosis of ovarian cancer
US6579973B1 (en)	1998-12-28	2003-06-17	Corixa Corporation	Compositions for the treatment and diagnosis of breast cancer and methods for their use
US7198920B1 (en)	1999-01-29	2007-04-03	Corika Corporation	HER-2/neu fusion proteins
AU2870300A (en) *	1999-02-05	2000-08-25	Genzyme Corporation	Use of cationic lipids to generate anti-tumor immunity
DK2204186T3 (en)	1999-02-17	2016-07-18	Csl Ltd	Immunogenic complexes, and related methods
AU2457100A (en)	1999-02-26	2000-09-14	Chiron S.P.A.	Enhancement of bactericidal activity of neisseria antigens with oligonucleotidescontaining cg motifs
AU2875700A (en)	1999-02-26	2000-09-14	Chiron Corporation	Microemulsions with adsorbed macromoelecules and microparticles
EP1163343B1 (de)	1999-03-12	2009-12-09	GlaxoSmithKline Biologicals S.A.	Antigene polypeptide aus neisseria meningitidis, dafür kodierende polynukleotide und entsprechende schützende antikörper
GB9909077D0 (en)	1999-04-20	1999-06-16	Smithkline Beecham Biolog	Novel compositions
MY125387A (en)	1999-03-19	2006-07-31	Smithkline Beecham Biologicals S A	Vaccine
FR2790955B1 (fr)	1999-03-19	2003-01-17	Assist Publ Hopitaux De Paris	Utilisation d'oligonucleotides stabilises comme principe actif antitumoral
JP2000262247A (ja) *	1999-03-19	2000-09-26	Asama Kasei Kk	免疫調節剤、免疫調節食品および免疫調節飼料
NZ514818A (en)	1999-04-02	2004-04-30	Corixa Corp	Compounds and methods for therapy and diagnosis of lung cancer
WO2000061151A2 (en) *	1999-04-12	2000-10-19	The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services	Oligodeoxynucleotide and its use to induce an immune response
US6977245B2 (en)	1999-04-12	2005-12-20	The United States Of America As Represented By The Department Of Health And Human Services	Oligodeoxynucleotide and its use to induce an immune response
US6558670B1 (en)	1999-04-19	2003-05-06	Smithkline Beechman Biologicals S.A.	Vaccine adjuvants
IL145982A0 (en)	1999-04-19	2002-07-25	Smithkline Beecham Biolog	Vaccines
EP1177439B1 (de) *	1999-04-29	2004-09-08	Coley Pharmaceutical GmbH	Screening nach modulatoren der funktion von immunstimulatorischer dna
GB9915204D0 (en) *	1999-06-29	1999-09-01	Smithkline Beecham Biolog	Vaccine
WO2001000232A2 (en) *	1999-06-29	2001-01-04	Smithkline Beecham Biologicals S.A.	Use of cpg as an adjuvant for hiv vaccine
US6514948B1 (en)	1999-07-02	2003-02-04	The Regents Of The University Of California	Method for enhancing an immune response
FR2795963A1 (fr) *	1999-07-08	2001-01-12	Pasteur Merieux Serums Vacc	Polynucleotide immunostimulant
SK782002A3 (en) *	1999-07-21	2003-08-05	Lexigen Pharm Corp	FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
GB9918319D0 (en)	1999-08-03	1999-10-06	Smithkline Beecham Biolog	Vaccine composition
US20050226890A1 (en) *	1999-08-12	2005-10-13	Cohen David I	Tat-based vaccine compositions and methods of making and using same
CA2380947C (en)	1999-08-19	2011-11-01	Dynavax Technologies Corporation	Methods of modulating an immune response using immunostimulatory sequences and compositions for use therein
JP2003509341A (ja) *	1999-08-27	2003-03-11	イネックスファーマスーティカルズコーポレイション	サイトカインの分泌刺激および免疫応答の誘導組成物
WO2001022972A2 (en) *	1999-09-25	2001-04-05	University Of Iowa Research Foundation	Immunostimulatory nucleic acids
US6949520B1 (en)	1999-09-27	2005-09-27	Coley Pharmaceutical Group, Inc.	Methods related to immunostimulatory nucleic acid-induced interferon
WO2001030847A1 (en)	1999-10-22	2001-05-03	Aventis Pasteur Limited	Modified gp100 and uses thereof
US7223398B1 (en)	1999-11-15	2007-05-29	Dynavax Technologies Corporation	Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof
WO2001045750A1 (en) *	1999-12-21	2001-06-28	The Regents Of The University Of California	Method for preventing an anaphylactic reaction
EP1322655B1 (de) *	2000-01-14	2007-11-14	The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services	Oligodeoxynukleotide und ihre verwendung zur induktion einer immunreaktion
AT409085B (de) *	2000-01-28	2002-05-27	Cistem Biotechnologies Gmbh	Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen
EP1253947A4 (de)	2000-01-31	2005-01-05	Univ California	Immunmodulatorische polynukleotide zur behandlung von infektionen durch intrazelluläre krankheitserreger
US7585847B2 (en) *	2000-02-03	2009-09-08	Coley Pharmaceutical Group, Inc.	Immunostimulatory nucleic acids for the treatment of asthma and allergy
FR2805265B1 (fr) *	2000-02-18	2002-04-12	Aventis Pasteur	Oligonucleotides immunostimulants
FR2805264B1 (fr) *	2000-02-18	2002-04-12	Aventis Pasteur	Oligonucleotides immunostimulants
US20030130217A1 (en) *	2000-02-23	2003-07-10	Eyal Raz	Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation
EP1259264A4 (de)	2000-02-23	2005-08-31	Univ California	VERFAHREN ZUR BEHANDLUNG VON ENTZüNDLICHEN DARMERKRANKUNGEN UND ANDEREN FORMEN VON GASTROINTESTINALEN ENTZüNDUNGEN
WO2001062778A2 (en) *	2000-02-23	2001-08-30	Smithkline Beecham Biologicals S.A.	Tumour-specific animal proteins
US20040002068A1 (en)	2000-03-01	2004-01-01	Corixa Corporation	Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
US20040131628A1 (en) *	2000-03-08	2004-07-08	Bratzler Robert L.	Nucleic acids for the treatment of disorders associated with microorganisms
US20030129251A1 (en)	2000-03-10	2003-07-10	Gary Van Nest	Biodegradable immunomodulatory formulations and methods for use thereof
US20020098199A1 (en)	2000-03-10	2002-07-25	Gary Van Nest	Methods of suppressing hepatitis virus infection using immunomodulatory polynucleotide sequences
US7129222B2 (en)	2000-03-10	2006-10-31	Dynavax Technologies Corporation	Immunomodulatory formulations and methods for use thereof
US7157437B2 (en)	2000-03-10	2007-01-02	Dynavax Technologies Corporation	Methods of ameliorating symptoms of herpes infection using immunomodulatory polynucleotide sequences
US20010046967A1 (en)	2000-03-10	2001-11-29	Gary Van Nest	Methods of preventing and treating respiratory viral infection using immunomodulatory polynucleotide
WO2001076642A1 (en) *	2000-04-07	2001-10-18	The Regents Of The University Of California	Synergistic improvements to polynucleotide vaccines
EP1278855B1 (de)	2000-04-21	2008-03-12	Corixa Corporation	Verbindungen und verfahren zur behandlung und diagnose von chlamydia-infektionen
PT1282702E (pt)	2000-05-10	2007-02-28	Ludwig Inst Cancer Res	Polipéptidos imunogénicos codificados por minigenes mage e suas utilizações
AU2001269695B2 (en)	2000-05-19	2007-02-15	Corixa Corporation	Prophylactic and therapeutic treatment of infectious, autoimmune and allergic diseases with mono and disaccharide-based compounds
EP1542732B1 (de)	2000-06-20	2009-09-16	Corixa Corporation	Fusionsproteine aus mycobakterium tuberculosis
JP2003535907A (ja)	2000-06-22	2003-12-02	ユニバーシティオブアイオワリサーチファウンデーション	抗体誘導性細胞溶解を促進し、そして癌を処置するための方法
AR029540A1 (es)	2000-06-28	2003-07-02	Corixa Corp	COMPOSICIONES Y METODOS PARA EL DIAGNoSTICO Y LA TERAPIA DE CA NCER DE PULMoN
ATE534402T1 (de)	2000-06-29	2011-12-15	Smithkline Beecham Biolog	Multivalente impfstoffzusammensetzung
GB0108364D0 (en)	2001-04-03	2001-05-23	Glaxosmithkline Biolog Sa	Vaccine composition
US7229623B1 (en)	2000-08-03	2007-06-12	Corixa Corporation	Her-2/neu fusion proteins
KR100917101B1 (ko) *	2000-08-04	2009-09-15	도요 보세키 가부시키가이샤	플렉시블 금속적층체 및 그 제조방법
UA79735C2 (uk)	2000-08-10	2007-07-25	Глаксосмітклайн Байолоджікалз С.А.	Очищення антигенів вірусу гепатиту b (hbv) для використання у вакцинах
US20080044435A1 (en) *	2004-03-16	2008-02-21	Cohen David I	Tat-Based Tolerogen Compositions and Methods of Making and Using Same
AU2001285421A1 (en) *	2000-08-10	2002-02-18	Henry M. Jackson Foundation For The Advancement Of Military Medicine	Vaccine against rsv
AU2001282475A1 (en) *	2000-08-25	2002-03-04	Yeda Research And Development Co. Ltd.	Methods of treatment or prevention of autoimmune diseases with CpG-containing polynucleotide
GB0022742D0 (en)	2000-09-15	2000-11-01	Smithkline Beecham Biolog	Vaccine
CA2419894A1 (en) *	2000-09-15	2002-03-21	Coley Pharmaceutical Gmbh	Process for high throughput screening of cpg-based immuno-agonist/antagonist
SI2266603T1 (sl)	2000-10-18	2012-12-31	Glaxosmithkline Biologicals S.A.	Tumorska cepiva
AU2002214127B2 (en)	2000-10-27	2007-06-07	J. Craig Venter Institute, Inc.	Nucleic acids and proteins from streptococcus groups A and B
AU2006216669A1 (en) *	2000-12-08	2006-08-31	3M Innovative Properties Company	Compositions and methods for targeted delivery of immune response modifiers
AU2001297693A1 (en) *	2000-12-08	2002-09-12	Coley Pharmaceutical Gmbh	Cpg-like nucleic acids and methods of use thereof
US6677347B2 (en) *	2000-12-08	2004-01-13	3M Innovative Properties Company	Sulfonamido ether substituted imidazoquinolines
ES2347525T3 (es) *	2000-12-27	2010-11-02	Dynavax Technologies Corporation	Polinucleotidos inmunomoduladores y metodos para usuarios.
EP1358885A1 (de) *	2001-01-12	2003-11-05	Amato Pharmaceutical Products, Ltd.	Antiallergische mittel
CN1496267A (zh) *	2001-01-12	2004-05-12	��ҩ��ʽ��	微生物感染防御剂
US7128911B2 (en)	2001-01-19	2006-10-31	Cytos Biotechnology Ag	Antigen arrays for treatment of bone disease
CA2436000A1 (en) *	2001-01-24	2002-08-08	Susumu Okabe	An antistress agent
DE10105234A1 (de)	2001-02-02	2002-08-29	Schoeller Textil Ag Sevelen	Textile Fläche
GB0103171D0 (en)	2001-02-08	2001-03-28	Smithkline Beecham Biolog	Vaccine composition
GB0105360D0 (en) *	2001-03-03	2001-04-18	Glaxo Group Ltd	Chimaeric immunogens
ES2298353T3 (es)	2001-03-22	2008-05-16	International Institute Of Cancer Immunology, Inc.	Peptido wt1 modificado.
US20030050268A1 (en) *	2001-03-29	2003-03-13	Krieg Arthur M.	Immunostimulatory nucleic acid for treatment of non-allergic inflammatory diseases
WO2002089747A2 (en)	2001-05-09	2002-11-14	Corixa Corporation	Compositions and methods for the therapy and diagnosis of prostate cancer
JP2005501004A (ja)	2001-05-21	2005-01-13	インターツェル・アクチェンゲゼルシャフト	核酸の安定化法
US6818787B2 (en) *	2001-06-11	2004-11-16	Xenoport, Inc.	Prodrugs of GABA analogs, compositions and uses thereof
GB0115176D0 (en)	2001-06-20	2001-08-15	Chiron Spa	Capular polysaccharide solubilisation and combination vaccines
US7785610B2 (en) *	2001-06-21	2010-08-31	Dynavax Technologies Corporation	Chimeric immunomodulatory compounds and methods of using the same—III
US20030199466A1 (en)	2001-06-21	2003-10-23	Fearon Karen L.	Chimeric immunomodulatory compounds and methods of using the same - ll
JP4370161B2 (ja) *	2001-06-29	2009-11-25	ノバルティスバクシンズアンドダイアグノスティックス，インコーポレーテッド	Ｈｃｖｅ１ｅ２ワクチン組成物
EP1417236A4 (de)	2001-07-10	2010-03-17	Corixa Corp	Zusammensetzungen und verfahren zur abgabe von proteinen und adjuvantien in einer mikrokügelchen-kapsel
GB0118249D0 (en)	2001-07-26	2001-09-19	Chiron Spa	Histidine vaccines
US7666674B2 (en)	2001-07-27	2010-02-23	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
GB0121591D0 (en)	2001-09-06	2001-10-24	Chiron Spa	Hybrid and tandem expression of neisserial proteins
AU2002318944A1 (en) *	2001-08-01	2003-02-17	Coley Pharmaceutical Gmbh	Methods and compositions relating to plasmacytoid dendritic cells
JP2005518343A (ja) *	2001-08-03	2005-06-23	メダレックス，インク．	新規なｐｇｃ−１イソフォームおよびその使用媒介型免疫治療を向上させるためのその使用
JP4607452B2 (ja)	2001-08-07	2011-01-05	ダイナバックステクノロジーズコーポレイション	免疫調節性組成物、製剤およびその使用方法
AU2002361468A1 (en) *	2001-08-14	2003-03-18	The Government Of The United States Of America As Represented By The Secretary Of Health And Human S	Method for rapid generation of mature dendritic cells
US7361352B2 (en)	2001-08-15	2008-04-22	Acambis, Inc.	Influenza immunogen and vaccine
KR100991644B1 (ko)	2001-08-17	2010-11-02	콜리 파마슈티칼 게엠베하	활성이 개량된 조합 모티프 면역자극성 올리고뉴클레오티드
ES2388170T3 (es)	2001-08-24	2012-10-09	Uvic Industry Partnerships Inc.	Proaerolisina que contiene secuencias de activación de proteasa y métodos de uso para el tratamiento del cáncer de próstata
WO2003020889A2 (en) *	2001-08-30	2003-03-13	3M Innovative Properties Company	Methods of maturing plasmacytoid dendritic cells using immune response modifier molecules
AU2002324937B2 (en) *	2001-09-07	2008-11-13	The Trustees Of Boston Univeristy	Method and composition for treating immune complex associated disorders
CA2492823A1 (en) *	2001-09-14	2003-03-27	Martin F. Bachmann	In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
JP4516748B2 (ja) *	2001-09-14	2010-08-04	サイトスバイオテクノロジーアーゲー	ウィルス様粒子中への免疫賦活物質のパッケージ化：調製法および使用法
EP1427826B1 (de)	2001-09-20	2011-04-20	Glaxo Group Limited	Codon-optimisierte HIV-RT-nef-Gag DNA Impfstoffe
US7514415B2 (en)	2002-08-01	2009-04-07	The United States Of America As Represented By The Department Of Health And Human Services	Method of treating inflammatory arthropathies with suppressors of CpG oligonucleotides
AU2002353783A1 (en)	2001-09-24	2003-04-07	The Government Of The United States Of America As Represented By The Secretary Of The Department Of	SUPPRESSORS OF CpG OLIGONUCLEOTIDES AND METHODS OF USE
US20030119774A1 (en) *	2001-09-25	2003-06-26	Marianna Foldvari	Compositions and methods for stimulating an immune response
EP1447091A4 (de)	2001-09-28	2008-02-13	Institute Of Can International	Neues verfahren zur induktion von antigen-spezifischen t-zellen
JPWO2003028758A1 (ja) *	2001-09-28	2005-01-13	治夫杉山	抗原特異的ｔ細胞の誘導方法
AR045702A1 (es)	2001-10-03	2005-11-09	Chiron Corp	Composiciones de adyuvantes.
EP1451581A4 (de) *	2001-10-05	2006-01-11	Coley Pharm Gmbh	Agonisten und antagonisten der signalisierung des toll-ähnlichen rezeptors 3
EP1478371A4 (de) *	2001-10-12	2007-11-07	Univ Iowa Res Found	Verfahren und produkte zur verbesserung der immunantworten mit imidazochinolin-verbindungen
TW200303759A (en) *	2001-11-27	2003-09-16	Schering Corp	Methods for treating cancer
AU2002358616A1 (en) *	2001-12-07	2003-06-17	Intercell Ag	Immunostimulatory oligodeoxynucleotides
US8080554B2 (en)	2001-12-12	2011-12-20	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Methods for using extracellular adenosine inhibitors and adenosine receptor inhibitors to enhance immune response and inflammation
CA2860702C (en)	2001-12-17	2019-02-26	Corixa Corporation	Compositions and methods for the therapy and diagnosis of inflammatory bowel disease
US7615227B2 (en) *	2001-12-20	2009-11-10	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Use of CpG oligodeoxynucleotides to induce angiogenesis
US8466116B2 (en)	2001-12-20	2013-06-18	The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Use of CpG oligodeoxynucleotides to induce epithelial cell growth
JP5153990B2 (ja) *	2001-12-21	2013-02-27	シーエスエル、リミテッド	免疫反応性試薬およびサポニンを含有する組成物、およびその使用方法
US7432371B2 (en) *	2002-02-07	2008-10-07	Covalent Partners, Llc	Nanofilm and membrane compositions
US20040034223A1 (en) *	2002-02-07	2004-02-19	Covalent Partners, Llc.	Amphiphilic molecular modules and constructs based thereon
US8088388B2 (en) *	2002-02-14	2012-01-03	United Biomedical, Inc.	Stabilized synthetic immunogen delivery system
AU2003215316A1 (en)	2002-02-20	2003-09-09	Chiron Corporation	Microparticles with adsorbed polypeptide-containing molecules
US7351413B2 (en)	2002-02-21	2008-04-01	Lorantis, Limited	Stabilized HBc chimer particles as immunogens for chronic hepatitis
US20050222060A1 (en) *	2002-03-15	2005-10-06	Bot Adrian L	Compositions and methods to initiate or enhance antibody and major-histocompatibility class I or class II-restricted t cell responses by using immunomodulatory, non-coding rna motifs
EP2258712A3 (de)	2002-03-15	2011-05-04	Multicell Immunotherapeutics, Inc.	Zusammensetzungen und Verfahren zur Einleitung bzw. Verstärkung von Antikörper- und Haupthistokompatibilität-Klasse-I- oder-Klasse-II-beschränkten T-Zell-Reaktionen unter Anwendung von Immunmodulierenden, nicht-codierenden RNA-Motiven
US20070037769A1 (en) *	2003-03-14	2007-02-15	Multicell Immunotherapeutics, Inc.	Compositions and methods to treat and control tumors by loading antigen presenting cells
JP4846200B2 (ja) *	2002-04-04	2011-12-28	コーリーファーマシューティカルゲーエムベーハー	免疫賦活性ｇ、ｕ含有オリゴリボヌクレオチド
US20030224013A1 (en) *	2002-04-19	2003-12-04	Cole Garry T.	Methods for protection against Coccidioides spp. infection using Coccidioides spp. urea amidohydrolase (Ure) protein
US20040009943A1 (en) *	2002-05-10	2004-01-15	Inex Pharmaceuticals Corporation	Pathogen vaccines and methods for using the same
US20040009944A1 (en) *	2002-05-10	2004-01-15	Inex Pharmaceuticals Corporation	Methylated immunostimulatory oligonucleotides and methods of using the same
AU2003229433B2 (en) *	2002-05-10	2008-04-24	Tekmira Pharmaceuticals Corporation	Methylated immunostimulatory oligonucleotides and methods of using the same
US20040013649A1 (en) *	2002-05-10	2004-01-22	Inex Pharmaceuticals Corporation	Cancer vaccines and methods of using the same
KR100456681B1 (ko) *	2002-05-22	2004-11-10	주식회사 대웅	박테리아의 염색체 ｄｎａ 파쇄물과 비독성리포폴리사카라이드를 포함하는 면역강화 및 조절 조성물
CA2388049A1 (en)	2002-05-30	2003-11-30	Immunotech S.A.	Immunostimulatory oligonucleotides and uses thereof
SE0201701D0 (sv) *	2002-06-05	2002-06-05	Gotovax Ab	Treatment of epithelial tumors and infections
WO2003103586A2 (en) *	2002-06-05	2003-12-18	Coley Pharmaceutical Group, Inc.	Method for treating autoimmune or inflammatory diseases with combinations of inhibitory oligonucleotides and small molecule antagonists of immunostimulatory cpg nucleic acids
WO2007095318A2 (en)	2006-02-13	2007-08-23	Fraunhofer Usa, Inc.	Influenza antigens, vaccine compositions, and related methods
PL375306A1 (en) *	2002-06-20	2005-11-28	Cytos Biotechnology Ag	Packaged virus-like particles for use as adjuvants: method of preparation and use
CA2490804C (en)	2002-06-28	2016-12-06	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Method of treating autoimmune diseases with interferon-beta and il-2r antagonist
DE10229872A1 (de)	2002-07-03	2004-01-29	Curevac Gmbh	Immunstimulation durch chemisch modifizierte RNA
US7807803B2 (en) *	2002-07-03	2010-10-05	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
US7605138B2 (en) *	2002-07-03	2009-10-20	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
US20040053880A1 (en) *	2002-07-03	2004-03-18	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
US7569553B2 (en)	2002-07-03	2009-08-04	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
US7576066B2 (en) *	2002-07-03	2009-08-18	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
WO2004007743A2 (en) *	2002-07-17	2004-01-22	Coley Pharmaceutical Gmbh	Use of cpg nucleic acids in prion-disease
DK1523582T3 (da)	2002-07-18	2009-03-02	Univ Washington	Hurtig, effektiv rensning af HSV-specifikke T-lymfocytter samt HSV-antigener identificeret derved
CA2484941A1 (en)	2002-07-24	2004-02-05	Intercell Ag	Antigens encoded by alternative reading frame from pathogenic viruses
MY149591A (en)	2002-08-02	2013-09-13	Glaxosmithkline Biolog Sa	Vaccines comprising l2 and/or l3 los from neisseria
JP4860923B2 (ja)	2002-08-15	2012-01-25	スリーエムイノベイティブプロパティズカンパニー	免疫刺激性組成物、および免疫応答の刺激方法
AR040996A1 (es)	2002-08-19	2005-04-27	Coley Pharm Group Inc	Acidos nucleicos inmunoestimuladores
GB0220194D0 (en)	2002-08-30	2002-10-09	Chiron Spa	Improved vesicles
US7378234B2 (en)	2002-09-13	2008-05-27	Intercell Ag	Method for isolating hepatitis C virus peptides
US20040106741A1 (en) *	2002-09-17	2004-06-03	Kriesel Joshua W.	Nanofilm compositions with polymeric components
US8263091B2 (en) *	2002-09-18	2012-09-11	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides
AU2003268737A1 (en) *	2002-10-02	2004-04-23	Mochida Pharmaceutical Co., Ltd.	Novel method of constructing monoclonal antibody
US8043622B2 (en)	2002-10-08	2011-10-25	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Method of treating inflammatory lung disease with suppressors of CpG oligonucleotides
CA2502414A1 (en)	2002-10-15	2004-04-29	Intercell Ag	Nucleic acids coding for adhesion factor of group b streptococcus, adhesion factors of group b streptococcus and further uses thereof
RU2356577C9 (ru)	2002-10-23	2009-08-10	Глаксосмитклайн Байолоджикалс С.А.	Способы вакцинации против малярии
JP2006512942A (ja) *	2002-10-25	2006-04-20	ユニバーシティーオブコネティカットヘルスセンター	制御細胞溶解による癌の免疫療法のための装置と方法
MXPA05004588A (es)	2002-10-29	2005-12-14	Coley Pharmaceutical Group Ltd	Metodos y productos relacionados con el tratamiento y prevencion de infeccion de virus de hepatitis c.
US7758876B2 (en) *	2002-11-01	2010-07-20	The United States Of America As Represented By The Department Of Health And Human Services	Method of preventing infections from bioterrorism agents with immunostimulatory CpG oligonucleotides
ATE466875T1 (de)	2002-11-15	2010-05-15	Novartis Vaccines & Diagnostic	Unerwartete oberflächenproteine in neisseria meningitidis
EP2322186A3 (de) *	2002-11-21	2011-07-13	Bayhill Therapeutics, Inc.	Verfahren und immunmodulierende Nukleinsäurekomponenten zur Vorbeugung und Behandlung von Krankheiten
GB0227346D0 (en)	2002-11-22	2002-12-31	Chiron Spa	741
WO2004052293A2 (en) *	2002-12-11	2004-06-24	Hawaii Biotech, Inc.	Recombinant vaccine against flavivirus infection
US20050287170A1 (en) *	2002-12-11	2005-12-29	Hawaii Biotech, Inc.	Subunit vaccine against West Nile viral infection
EP1578954A4 (de) *	2002-12-11	2010-08-11	Coley Pharm Group Inc	5'-cpg-nukleinsäuren und verwendungsverfahren
KR100525321B1 (ko) *	2002-12-13	2005-11-02	안웅식	파필로마바이러스 항원 단백질 및ＣｐＧ-올리고데옥시뉴클레오타이드를 포함하는파필로마바이러스 유발 질환의 예방 또는 치료용 약제학적조성물
US8158768B2 (en) *	2002-12-23	2012-04-17	Dynavax Technologies Corporation	Immunostimulatory sequence oligonucleotides and methods of using the same
ATE544772T1 (de) *	2002-12-23	2012-02-15	Dynavax Tech Corp	Immunstimulierende sequenz-oligonukleotide und verwendungsverfahren dafür
CA2508985A1 (en) *	2002-12-23	2004-07-15	Dynavax Technologies Corporation	Branched immunomodulatory compounds and methods of using the same
CA2511512C (en)	2002-12-27	2013-10-29	Chiron Corporation	Immunogenic compositions containing phospholipid
WO2004060319A2 (en) *	2002-12-30	2004-07-22	3M Innovative Properties Company	Immunostimulatory combinations
HUE026376T2 (en)	2003-01-06	2016-05-30	Corixa Corp	Certain aminoalkyl glucosamide phosphate compounds and their use
US7960522B2 (en)	2003-01-06	2011-06-14	Corixa Corporation	Certain aminoalkyl glucosaminide phosphate compounds and their use
AU2004209660A1 (en)	2003-02-03	2004-08-19	Fraunhofer Usa, Inc.	System for expression of genes in plants
WO2004071459A2 (en) *	2003-02-13	2004-08-26	3M Innovative Properties Company	Methods and compositions related to irm compounds and toll-like receptor 8
DE602004030541D1 (de)	2003-02-20	2011-01-27	Univ Connecticut Health Ct	Verfahren zur herstellung von alpha (2) makroglobulin-antigen-molekül-komplexen
GB2398783A (en)	2003-02-26	2004-09-01	Antonio Lanzavecchia	A method for producing immortalised human B memory lymphocytes
JP2006519020A (ja) *	2003-02-27	2006-08-24	スリーエムイノベイティブプロパティズカンパニー	Ｔｌｒ介在生物活性の選択的調節
EP2287311A1 (de)	2003-03-04	2011-02-23	Intercell AG	Streptococcus-pyogenes-Antigene
US8110582B2 (en)	2003-03-04	2012-02-07	3M Innovative Properties Company	Prophylactic treatment of UV-induced epidermal neoplasia
US7179253B2 (en)	2003-03-13	2007-02-20	3M Innovative Properties Company	Method of tattoo removal
KR20050109562A (ko) *	2003-03-13	2005-11-21	쓰리엠 이노베이티브 프로퍼티즈 컴파니	피부의 질을 개선시키는 방법
US7704514B2 (en)	2003-03-24	2010-04-27	Intercell Ag	Vaccines
US20040192585A1 (en) *	2003-03-25	2004-09-30	3M Innovative Properties Company	Treatment for basal cell carcinoma
US7537767B2 (en)	2003-03-26	2009-05-26	Cytis Biotechnology Ag	Melan-A- carrier conjugates
US20060172959A1 (en) *	2003-03-26	2006-08-03	Dan Smith	Selected rna motifs to include cell death and/or apoptosis
WO2004084940A1 (en) *	2003-03-26	2004-10-07	Cytos Biotechnology Ag	Packaging of immunostimulatory oligonucleotides into virus-like particles: method of preparation and use
US7628994B2 (en)	2003-03-31	2009-12-08	Intercell Ag	S. epidermidis antigens
AU2004226605A1 (en) *	2003-04-02	2004-10-14	Coley Pharmaceutical Group, Ltd.	Immunostimulatory nucleic acid oil-in-water formulations for topical application
WO2004108072A2 (en) *	2003-04-10	2004-12-16	3M Innovative Properties Company	Delivery of immune response modifier compounds using metal-containing particulate support materials
US20040265351A1 (en) *	2003-04-10	2004-12-30	Miller Richard L.	Methods and compositions for enhancing immune response
SE0301109D0 (sv) *	2003-04-14	2003-04-14	Mallen Huang	Nucleotide vaccine composition
US7635487B2 (en)	2003-04-15	2009-12-22	Intercell Ag	S. pneumoniae antigens
US20040214851A1 (en) *	2003-04-28	2004-10-28	3M Innovative Properties Company	Compositions and methods for induction of opioid receptors
AU2004235952A1 (en)	2003-05-07	2004-11-18	Intercell Ag	Streptococcus agalactiae antigens I + II
CA2527756C (en)	2003-05-15	2014-05-06	Japan Science And Technology Agency	Immunostimulating agents
ES2427641T3 (es)	2003-05-22	2013-10-31	Ibio, Inc.	Molécula vehículo recombinante para la expresión, el suministro y la purificación de polipéptidos diana
EP2267006A1 (de)	2003-05-30	2010-12-29	Intercell AG	Enterokokken-Antigene
DE602004022286D1 (de)	2003-06-02	2009-09-10	Novartis Vaccines & Diagnostic	Immunogene zusammensetzungen auf basis von biologisch abbaubaren mikroteilchen enthaltend ein diphtherie- und ein tetanustoxoid
WO2005000884A1 (en)	2003-06-05	2005-01-06	The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services	Poly-gamma-glutamic conjugates for eliciting immune responses directed against bacilli
KR20060016817A (ko) *	2003-06-20	2006-02-22	콜리 파마슈티칼 게엠베하	소분자 톨-유사 수용체 (ｔｌｒ) 길항제
CN100404070C (zh) *	2003-07-10	2008-07-23	赛托斯生物技术公司	包装的病毒样颗粒
US20050013812A1 (en) *	2003-07-14	2005-01-20	Dow Steven W.	Vaccines using pattern recognition receptor-ligand:lipid complexes
JP2007501252A (ja) *	2003-08-05	2007-01-25	スリーエムイノベイティブプロパティズカンパニー	免疫応答調整剤を含有する製剤
AR045260A1 (es) *	2003-08-12	2005-10-19	3M Innovative Properties Co	Compuestos que contienen imidazo-oxima sustituidos
US20060035242A1 (en)	2004-08-13	2006-02-16	Michelitsch Melissa D	Prion-specific peptide reagents
JP2007504145A (ja) *	2003-08-25	2007-03-01	スリーエムイノベイティブプロパティズカンパニー	免疫刺激性の組み合わせおよび治療
RU2006105101A (ru) *	2003-08-27	2007-10-10	3М Инновейтив Пропертиз Компани (US)	Арилокси и арилалкиленокси замещенные имидазохинолины
AU2004268665A1 (en) *	2003-09-02	2005-03-10	3M Innovative Properties Company	Methods related to the treatment of mucosal associated conditions
US20050054665A1 (en) *	2003-09-05	2005-03-10	3M Innovative Properties Company	Treatment for CD5+ B cell lymphoma
AU2004274430A1 (en)	2003-09-12	2005-03-31	Antigenics, Inc.	Vaccine for treatment and prevention of herpes simplex virus infection
AU2004275876B2 (en) *	2003-09-25	2011-03-31	Coley Pharmaceutical Gmbh	Nucleic acid-lipophilic conjugates
AU2004277342B2 (en)	2003-10-02	2010-12-16	Glaxosmithkline Biologicals S.A.	Pertussis antigens and use thereof in vaccination
BRPI0414856A (pt) *	2003-10-03	2006-11-21	3M Innovative Properties Co	imidazoquinolinas alcóxi-substituìdas
US20090075980A1 (en) *	2003-10-03	2009-03-19	Coley Pharmaceutical Group, Inc.	Pyrazolopyridines and Analogs Thereof
US7544697B2 (en) *	2003-10-03	2009-06-09	Coley Pharmaceutical Group, Inc.	Pyrazolopyridines and analogs thereof
EP1675614A2 (de) *	2003-10-11	2006-07-05	Inex Pharmaceuticals Corp.	Verfahren und zusammensetzungen zur verbesserung der inhärenten immunität und antikörper-abhängigen zellulären zytotoxizität
EP1678303A2 (de) *	2003-10-30	2006-07-12	Coley Pharmaceutical GmbH	C-klasse-oligonukleotidanaloge mit verbesserter immunstimulatorischer potency
US20050239733A1 (en) *	2003-10-31	2005-10-27	Coley Pharmaceutical Gmbh	Sequence requirements for inhibitory oligonucleotides
US20050096259A1 (en) *	2003-10-31	2005-05-05	3M Innovative Properties Company	Neutrophil activation by immune response modifier compounds
US20050100983A1 (en) *	2003-11-06	2005-05-12	Coley Pharmaceutical Gmbh	Cell-free methods for identifying compounds that affect toll-like receptor 9 (TLR9) signaling
AU2004291101A1 (en)	2003-11-14	2005-06-02	3M Innovative Properties Company	Oxime substituted imidazo ring compounds
JP2007511535A (ja) *	2003-11-14	2007-05-10	スリーエムイノベイティブプロパティズカンパニー	ヒドロキシルアミン置換イミダゾ環化合物
EP1687307B1 (de) *	2003-11-25	2016-01-06	3M Innovative Properties Company	Substituierte imidazoringsysteme und verfahren
US20050277127A1 (en) *	2003-11-26	2005-12-15	Epitomics, Inc.	High-throughput method of DNA immunogen preparation and immunization
US20050287118A1 (en) *	2003-11-26	2005-12-29	Epitomics, Inc.	Bacterial plasmid with immunological adjuvant function and uses thereof
US20050226878A1 (en) *	2003-12-02	2005-10-13	3M Innovative Properties Company	Therapeutic combinations and methods including IRM compounds
EP1689361A4 (de) *	2003-12-02	2009-06-17	3M Innovative Properties Co	Therapeutische kombinationen und verfahren mit irm-verbindungen
EP1708745B1 (de)	2003-12-23	2012-04-18	Arbor Vita Corporation	Antikörper für onkogene stämme von hpv und verfahren zu deren verwendung
JP4817599B2 (ja) *	2003-12-25	2011-11-16	独立行政法人科学技術振興機構	免疫活性増強剤とこれを用いた免疫活性の増強方法
EP1701955A1 (de) *	2003-12-29	2006-09-20	3M Innovative Properties Company	Arylalkenyl- und arylalkinylsubstituierte imidazochinoline
WO2005067500A2 (en) *	2003-12-30	2005-07-28	3M Innovative Properties Company	Enhancement of immune responses
CA2551399A1 (en) *	2003-12-30	2005-07-21	3M Innovative Properties Company	Imidazoquinolinyl, imidazopyridinyl, and imidazonaphthyridinyl sulfonamides
WO2005072290A2 (en) *	2004-01-23	2005-08-11	Joslin Diabetes Center	Methods of treating, reducing, or preventing autoimmune conditions
CA2555274A1 (en)	2004-02-05	2005-08-25	The Ohio State University Research Foundation	Chimeric vegf peptides
US20050181035A1 (en) *	2004-02-17	2005-08-18	Dow Steven W.	Systemic immune activation method using non CpG nucleic acids
CA2555390C (en) *	2004-02-19	2014-08-05	Coley Pharmaceutical Group, Inc.	Immunostimulatory viral rna oligonucleotides
US20050208482A1 (en) *	2004-03-16	2005-09-22	Cohen David I	Tat-based immunomodulatory compositions and methods for their discovery and use
EP1734975B1 (de)	2004-03-19	2015-06-10	Herbs Spring, LLC	Pflanzliche therapie zur behandlung von nahrungsmittelallergien
US8697873B2 (en) *	2004-03-24	2014-04-15	3M Innovative Properties Company	Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
TWI235440B (en) *	2004-03-31	2005-07-01	Advanced Semiconductor Eng	Method for making leadless semiconductor package
WO2005110013A2 (en) *	2004-04-09	2005-11-24	3M Innovative Properties Company	Methods, compositions, and preparations for delivery of immune response modifiers
CN101426524A (zh) *	2004-04-28	2009-05-06	3M创新有限公司	用于粘膜接种疫苗的组合物和方法
JP5014122B2 (ja)	2004-05-06	2012-08-29	アメリカ合衆国	ブドウ膜炎の治療のための方法および組成物
AU2005285513B2 (en)	2004-05-25	2011-02-24	Oregon Health And Science University	SIV and HIV vaccination using RhCMV- and HCMV-based vaccine vectors
PT1765310E (pt)	2004-05-28	2016-03-01	Oryxe	Uma mistura para entrega transdérmica de compostos de baixo e alto peso molecular
US20050267145A1 (en) *	2004-05-28	2005-12-01	Merrill Bryon A	Treatment for lung cancer
US8017779B2 (en) *	2004-06-15	2011-09-13	3M Innovative Properties Company	Nitrogen containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
WO2006009832A1 (en) *	2004-06-18	2006-01-26	3M Innovative Properties Company	Substituted imidazo ring systems and methods
WO2006038923A2 (en) *	2004-06-18	2006-04-13	3M Innovative Properties Company	Aryl substituted imidazonaphthyridines
US8026366B2 (en) *	2004-06-18	2011-09-27	3M Innovative Properties Company	Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
US7915281B2 (en) *	2004-06-18	2011-03-29	3M Innovative Properties Company	Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and method
NZ553244A (en) *	2004-07-18	2009-10-30	Csl Ltd	Immuno stimulating complex and oligonucleotide formulations for inducing enhanced interferon-gamma responses
ES2534288T3 (es)	2004-08-03	2015-04-21	Innate Pharma	Composiciones terapéuticas contra el cáncer que seleccionan como objetivo 4Ig-B7-H3
GB0417494D0 (en)	2004-08-05	2004-09-08	Glaxosmithkline Biolog Sa	Vaccine
EP1786450A4 (de) *	2004-08-27	2009-11-11	3M Innovative Properties Co	Hiv-immunstimulatorische zusammensetzungen
US20090270443A1 (en) *	2004-09-02	2009-10-29	Doris Stoermer	1-amino imidazo-containing compounds and methods
JP2008513406A (ja)	2004-09-22	2008-05-01	グラクソスミスクラインバイオロジカルズソシエテアノニム	免疫原性組成物
EP2149583B1 (de)	2004-09-24	2015-10-28	Novartis AG	Modifiziertes VP1-Capsid Protein von Parvovirus B19
JP2008000001A (ja) *	2004-09-30	2008-01-10	Osaka Univ	免疫刺激オリゴヌクレオチドおよびその医薬用途
EP3312272B1 (de)	2004-10-08	2019-08-28	The Government of The United States of America as represented by The Secretary of The Department of Health and Human Services	Modulation der replikationsrate durch verwendung von seltener verwendeten synonymen kodonen
US20070243215A1 (en) *	2004-10-08	2007-10-18	Miller Richard L	Adjuvant for Dna Vaccines
MY159370A (en) *	2004-10-20	2016-12-30	Coley Pharm Group Inc	Semi-soft-class immunostimulatory oligonucleotides
WO2006065549A2 (en)	2004-12-03	2006-06-22	Medical University Of Ohio	Attenuated vaccine useful for immunizations against coccidioides spp. infections
US20110070575A1 (en) *	2004-12-08	2011-03-24	Coley Pharmaceutical Group, Inc.	Immunomodulatory Compositions, Combinations and Methods
WO2006065751A2 (en) *	2004-12-13	2006-06-22	Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services	Cpg oligonucleotide prodrugs, compositions thereof and associated therapeutic methods
EP2394650A1 (de)	2004-12-30	2011-12-14	3M Innovative Properties Co.	Verwendung von Resiquimod zur Behandlung von Hautmetastasen
ES2392648T3 (es)	2004-12-30	2012-12-12	3M Innovative Properties Company	Compuestos quirales sustituidos que contienen un núcleo 1,2-imidazo-4,5-c condensado
CA2592904C (en)	2004-12-30	2015-04-07	3M Innovative Properties Company	Chiral fused [1,2]imidazo[4,5-c] ring compounds
NZ555937A (en)	2005-01-27	2009-05-31	Childrens Hosp & Res Ct Oak	GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis
US9248127B2 (en) *	2005-02-04	2016-02-02	3M Innovative Properties Company	Aqueous gel formulations containing immune response modifiers
WO2006086634A2 (en)	2005-02-11	2006-08-17	Coley Pharmaceutical Group, Inc.	Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods
WO2006091915A2 (en) *	2005-02-24	2006-08-31	Coley Pharmaceutical Group, Inc.	Immunostimulatory oligonucleotides
GB0504436D0 (en)	2005-03-03	2005-04-06	Glaxosmithkline Biolog Sa	Vaccine
US8101345B1 (en)	2005-03-25	2012-01-24	Isis Pharmaceuticals, Inc.	Proinflammatory nucleic acids
KR20070121814A (ko)	2005-03-31	2007-12-27	글락소스미스클라인 바이오로지칼즈 에스.에이.	클라미디아 감염에 대비한 백신
AU2006232375A1 (en)	2005-04-01	2006-10-12	Coley Pharmaceutical Group, Inc.	1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
AU2006232377A1 (en)	2005-04-01	2006-10-12	Coley Pharmaceutical Group, Inc.	Pyrazolopyridine-1,4-diamines and analogs thereof
EP1865967A4 (de) *	2005-04-08	2011-02-09	Chimerix Inc	Verbindungen, zusammensetzungen und verfahren zur behandlung viraler infektionen und anderer erkrankungen
KR20080008350A (ko) *	2005-04-08	2008-01-23	콜레이 파마시티컬 그룹, 인코포레이티드	감염성 질환에 의해 악화된 천식의 치료 방법
JP2008535862A (ja) *	2005-04-08	2008-09-04	キメリクス，インコーポレイテッド	ポックスウイルス感染の治療のための化合物、組成物および方法
AU2006241166A1 (en) *	2005-04-25	2006-11-02	3M Innovative Properties Company	Immunostimulatory compositions
EP1899467A2 (de) *	2005-04-26	2008-03-19	Coley Pharmaceutical GmbH	Modifizierte oligoribonukleotidanaloge mit verbesserter immunstimulierender aktivität
US8470338B2 (en)	2005-04-29	2013-06-25	Glaxosmithkline Biologicals, S.A.	Method for preventing or treating M tuberculosis infection
AU2006257664B2 (en)	2005-06-14	2013-01-10	Protox Therapeutics Incorporated	Method of treating or preventing benign prostatic hyperplasia using modified pore-forming proteins
ES2531483T3 (es)	2005-06-15	2015-03-16	The Ohio State University Research Foundation	Péptidos HER-2
GB0513421D0 (en)	2005-06-30	2005-08-03	Glaxosmithkline Biolog Sa	Vaccines
PL2380584T3 (pl)	2005-07-01	2014-03-31	Index Pharmaceuticals Ab	Sposób do immunostymulacji
WO2007004979A1 (en)	2005-07-01	2007-01-11	Index Pharmaceuticals Ab	Method for modulating responsiveness to steroids
JP2009500412A (ja) *	2005-07-07	2009-01-08	コーリーファーマシューティカルグループ，インコーポレイテッド	癌の処置のための、抗ｃｔｌａ−４抗体とｃｐｇモチーフ含有合成オリゴデオキシヌクレオチドとの組み合わせ治療
WO2007008904A2 (en) *	2005-07-08	2007-01-18	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Targeting poly-gamma-glutamic acid to treat staphylococcus epidermidis and related infections
CA2614884A1 (en)	2005-07-11	2007-01-18	Globeimmune, Inc	Compositions and methods for eliciting an immune response to escape mutants of targeted therapies
EP1919504B1 (de)	2005-08-03	2013-10-16	iBio, Inc.	Antikörper gegen bacillus anthracis protektiv antigen
US20100130425A1 (en)	2005-09-09	2010-05-27	Oregon Health & Science University	Use of toll-like receptor ligands in treating excitotoxic injury, ischemia and/or hypoxia
BRPI0616069A2 (pt) *	2005-09-16	2011-06-07	Coley Pharm Gmbh	modulação de propriedades imunomoduladoras de ácido ribonucléico interferente pequeno (sirna) através de modificação de nucleotìdeo
AU2006337419A1 (en) *	2005-09-16	2007-08-09	Coley Pharmaceutical Gmbh	Immunostimulatory single-stranded ribonucleic acid with phosphodiester backbone
US20070081972A1 (en) *	2005-09-30	2007-04-12	The University Of Iowa Research Foundation	Polymer-based delivery system for immunotherapy of cancer
US8895522B2 (en)	2005-10-28	2014-11-25	Index Pharmaceuticals Ab	Composition and method for the prevention, treatment and/or alleviation of an inflammatory disease
BRPI0618857B1 (pt)	2005-11-25	2022-07-19	Zoetis Belgium S.A	Oligonucleotídeo de rna isolado, e método para regular negativamente células reguladoras cd4+ imunossupressoras
AU2006326405B2 (en)	2005-12-13	2013-10-31	President And Fellows Of Harvard College	Scaffolds for cell transplantation
US20070184068A1 (en)	2005-12-14	2007-08-09	Cytos Biotechnology Ag	Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity
GB0607088D0 (en)	2006-04-07	2006-05-17	Glaxosmithkline Biolog Sa	Vaccine
EA014107B1 (ru)	2005-12-22	2010-10-29	Глаксосмитклайн Байолоджикалс С.А.	Вакцина, содержащая конъюгаты капсульных полисахаридов streptococcus pneumoniae
WO2007082105A2 (en)	2006-01-16	2007-07-19	Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Chlamydia vaccine
BRPI0707154B8 (pt)	2006-01-17	2022-12-20	Forsgren Arne	composição de vacina
EP1991678B2 (de)	2006-02-15	2020-07-15	Rechtsanwalt Thomas Beck	Zusammensetzungen und verfahren für oligonukleotidformulierungen
WO2007100634A2 (en)	2006-02-22	2007-09-07	3M Innovative Properties Company	Immune response modifier conjugates
US7842299B2 (en)	2006-03-14	2010-11-30	Oregon Health & Science University	Methods for producing an immune response to tuberculosis
US20100021503A1 (en)	2006-03-30	2010-01-28	Glaxosmithkline Biologicals S.A.	Immunogenic composition
WO2007119815A1 (ja)	2006-04-14	2007-10-25	Kyowa Hakko Kirin Co., Ltd.	Ｔｏｌｌ様受容体９作動薬
US8592566B2 (en)	2006-05-31	2013-11-26	Toray Industries, Inc.	Immunostimulatory oligonucleotides and use thereof in pharmaceuticals
MX2008015372A (es)	2006-06-02	2009-03-23	Glaxosmithkline Biolog Sa	Método para identificar si un paciente sera respondedor o no a inmunoterapia.
KR100906970B1 (ko)	2006-06-03	2009-07-10	주식회사 바이오씨에스	피부 면역질환에 대한 ＣｐＧ 올리고데옥시뉴클레오티드의치료학적 용도
US20080026986A1 (en) *	2006-06-05	2008-01-31	Rong-Fu Wang	Reversal of the suppressive function of specific t cells via toll-like receptor 8 signaling
ES2738986T3 (es)	2006-06-12	2020-01-28	Kuros Biosciences Ag	Procesos para empaquetar oligonucleótidos en partículas de tipo viral de bacteriófagos de ARN
US20090246224A1 (en)	2006-06-12	2009-10-01	Nathalie Devos	Vaccine
EP2292646A3 (de)	2006-07-07	2011-06-08	Intercell AG	Kleine Streptococcus-pyogenes-Antigene und Verwendung dafür
WO2008094183A2 (en) *	2006-07-11	2008-08-07	University Of Connecticut	Use of conditional plasmodium strains lacking nutrient transporters in malaria vaccination
US8153116B2 (en)	2006-07-11	2012-04-10	University Of Connecticut	Use of conditional plasmodium strains lacking an essential gene in malaria vaccination
US7906506B2 (en) *	2006-07-12	2011-03-15	3M Innovative Properties Company	Substituted chiral fused [1,2] imidazo [4,5-c] ring compounds and methods
DE102006035618A1 (de) *	2006-07-31	2008-02-07	Curevac Gmbh	Nukleinsäure der Formel (I): GlXmGn, insbesondere als immunstimulierendes Adjuvanz
EP2046954A2 (de)	2006-07-31	2009-04-15	Curevac GmbH	Nukleinsäure der formel (i): gixngn, oder (ii): cixmcn, insbesondere als immunstimulierendes mittel/adjuvans
EP2066344B2 (de)	2006-09-07	2016-06-29	GlaxoSmithKline Biologicals S.A.	Inaktiviertes Poliovirus Mischimpfstoff
EP2059526A2 (de)	2006-09-15	2009-05-20	Intercell AG	Borrelia-antigene
US20090181078A1 (en)	2006-09-26	2009-07-16	Infectious Disease Research Institute	Vaccine composition containing synthetic adjuvant
PL2484375T3 (pl)	2006-09-26	2018-09-28	Infectious Disease Research Institute	Kompozycja szczepionki zawierająca syntetyczny adiuwant
PT2078080E (pt)	2006-09-27	2015-09-18	Coley Pharm Gmbh	Análogos dos oligonucleotídeos cpg que contêm análogos t hidrofóbicos com atividade imunoestimulante potenciada
WO2008139262A2 (en) *	2006-10-26	2008-11-20	Coley Pharmaceutical Gmbh	Oligoribonucleotides and uses thereof
EP3276349B1 (de)	2006-11-01	2019-08-07	Ventana Medical Systems, Inc.	Haptene, haptenkonjugate, zusammensetzungen daraus und verfahren für ihre herstellung und verwendung
US20090142362A1 (en) *	2006-11-06	2009-06-04	Avant Immunotherapeutics, Inc.	Peptide-based vaccine compositions to endogenous cholesteryl ester transfer protein (CETP)
EP2094849B1 (de) *	2006-11-09	2014-01-08	Dynavax Technologies Corporation	Langfristige modifikation einer erkrankung mithilfe immunstimulatorischer oligonukleotide
EP1923069A1 (de)	2006-11-20	2008-05-21	Intercell AG	Schutzpeptide gegen S. pneumoniae und diesbezügliche Zusammensetzungen, Verfahren und Verwendungen
US20080149123A1 (en)	2006-12-22	2008-06-26	Mckay William D	Particulate material dispensing hairbrush with combination bristles
WO2008084072A2 (en)	2007-01-12	2008-07-17	Intercell Ag	Protective proteins of s. agalactiae, combinations thereof and methods of using the same
EP2125868B1 (de)	2007-02-28	2015-06-10	The Govt. Of U.S.A. As Represented By The Secretary Of The Department Of Health And Human Services	Brachyurie-polypeptide und verwendungsverfahren
PL2137210T3 (pl)	2007-03-02	2017-06-30	Glaxosmithkline Biologicals Sa	Nowy sposób i kompozycje
EP2125853A1 (de) *	2007-03-07	2009-12-02	Nventa Biopharmaceuticals Corporation	Doppelsträngige lna-zusammensetzungen
BRPI0809247A2 (pt)	2007-03-19	2014-09-09	Globeimmune Inc	Composições e métodos para a ablação do escape mutacional de terapias marcadas para câncer.
WO2008124647A2 (en)	2007-04-04	2008-10-16	Infectious Disease Research Institute	Immunogenic compositions comprising mycobacterium tuberculosis polypeptides and fusions thereof
US9452209B2 (en)	2007-04-20	2016-09-27	Glaxosmithkline Biologicals Sa	Influenza vaccine
US8778348B2 (en)	2007-04-28	2014-07-15	Ibio Inc.	Trypanosoma antigens, vaccine compositions, and related methods
EP2360177A1 (de)	2007-05-02	2011-08-24	Intercell AG	Klebsiella-Antigene
EA201490303A1 (ru)	2007-05-02	2014-05-30	Глаксосмитклайн Байолоджикалс С.А.	Вакцина
EP2573176B1 (de) *	2007-05-04	2016-04-06	InDex Pharmaceuticals AB	Tumorwachstumshemmende Verbindungen und Verfahren zu ihrer Verwendung
WO2008142509A2 (en) *	2007-05-17	2008-11-27	Coley Pharmaceutical Group, Inc.	Class a oligonucleotides with immunostimulatory potency
SI2170353T1 (sl) *	2007-05-18	2015-09-30	Adiu Tide Pharmaceuticals Gmbh	Fosfatno modificirani oligonukleotidni analogi z imunostimulatorno aktivnostjo
CA2687178C (en)	2007-05-23	2014-02-04	Ventana Medical Systems, Inc.	Polymeric carriers for immunohistochemistry and in situ hybridization
KR101238795B1 (ko)	2007-05-24	2013-03-07	글락소스미스클라인 바이오로지칼즈 에스.에이.	동결건조 항원 조성물
WO2008145400A2 (en)	2007-05-31	2008-12-04	Medigene Ag	Mutated structural protein of a parvovirus
EP2012122A1 (de)	2007-07-06	2009-01-07	Medigene AG	Strukturproteine von mutierten Parvoviren als Impfstoffe
EP2511291A3 (de)	2007-06-18	2012-11-07	Intercell AG	Chlamydia-Antigene
PT2167121E (pt)	2007-06-26	2015-12-02	Glaxosmithkline Biolog Sa	Vacina compreendendo conjugados de polissacáridos capsulares de streptococcus pneumoniae
DK2170384T3 (en)	2007-07-02	2016-07-25	Etubics Corp	METHODS AND COMPOSITIONS FOR THE PRODUCTION OF AN adenovirus vector for use in higher vaccination
CA2692933C (en)	2007-07-11	2016-10-18	Fraunhofer Usa, Inc.	Yersinia pestis antigens, vaccine compositions, and related methods
KR101580660B1 (ko)	2007-08-02	2015-12-28	바이오앤드백스 파마슈티칼즈, 리미티드.	다중체 다중-에피토프 인플루엔자 백신
JP2010535504A (ja)	2007-08-03	2010-11-25	プレジデントアンドフェロウズオブハーバードカレッジ	クラミジア抗原
US7879812B2 (en)	2007-08-06	2011-02-01	University Of Iowa Research Foundation	Immunomodulatory oligonucleotides and methods of use therefor
UY31285A1 (es)	2007-08-13	2009-03-31		Vacunas
CN101835487A (zh) *	2007-08-21	2010-09-15	戴纳瓦克斯技术公司	制备和使用流感蛋白质的组合物和方法
JP2010536907A (ja) *	2007-08-31	2010-12-02	ニューリミューンセラピューティクスエイジー	患者にアミロイドーシスおよびタンパク質凝集性障害における特異的免疫応答をもたらす方法
WO2009030254A1 (en)	2007-09-04	2009-03-12	Curevac Gmbh	Complexes of rna and cationic peptides for transfection and for immunostimulation
NZ583796A (en)	2007-09-17	2011-12-22	Oncomethylome Sciences Sa	Improved detection of mage-a expression
CN101820908A (zh)	2007-10-09	2010-09-01	科利制药公司	包含改性糖部分的免疫刺激寡核苷酸类似物
NZ585556A (en)	2007-11-07	2012-07-27	Celldex Therapeutics Inc	Antibodies that bind human dendritic and epithelial cell 205 (dec-205)
US20100266604A1 (en)	2007-11-09	2010-10-21	The Salk Institute For Biological Studies	Use of tam receptor inhibitors as immunoenhancers and tam activators as immunosuppressors
WO2009073179A2 (en)	2007-12-03	2009-06-11	President And Fellows Of Harvard College	Chlamydia antigens
EP2244695A1 (de)	2007-12-07	2010-11-03	Novartis AG	Zusammensetzungen zur induktion von immunantworten
CA2710600C (en)	2007-12-24	2017-06-06	Id Biomedical Corporation Of Quebec	Recombinant rsv antigens
CN105055432A (zh) *	2008-01-25	2015-11-18	奇默里克斯公司	治疗病毒感染的方法
ES2537703T3 (es)	2008-01-31	2015-06-11	Curevac Gmbh	Ácidos nucleicos que comprenden la fórmula (NuGlXmGnNv)a y sus derivados como agentes/adyuvantes inmunoestimuladores
CA2715460C (en)	2008-02-13	2020-02-18	President And Fellows Of Harvard College	Continuous cell programming devices
WO2009105641A2 (en) *	2008-02-20	2009-08-27	New York University	Preventing and treating amyloid-beta deposition by stimulation of innate immunity
CA2717870A1 (en)	2008-03-10	2009-09-17	Children's Hospital & Research Center At Oakland	Chimeric factor h binding proteins (fhbp) containing a heterologous b domain and methods of use
EP2265634A2 (de)	2008-03-17	2010-12-29	Intercell AG	Peptide schutzmittel gegen s. pneumoniae und zusammensetzungen, verfahren und anwendung im zusammenhang damit
EP3329931B1 (de)	2008-04-18	2022-06-08	The General Hospital Corporation	Immuntherapien mit selbst-zusammensetzenden vakzinen
US8815817B2 (en) *	2008-05-15	2014-08-26	Dynavax Technologies Corporation	Long term disease modification using immunostimulatory oligonucleotides
EP2278979A4 (de)	2008-05-21	2012-09-26	Us Gov Health & Human Serv	Verfahren zur behandlung von pneumokoniose mit oligodesoxynukleotiden
AU2009248810B2 (en)	2008-05-23	2013-12-05	The Regents Of The University Of Michigan	Nanoemulsion vaccines
DK2995925T3 (da)	2008-06-05	2022-02-21	Ventana Med Syst Inc	Sammensætning til histokemisk processering
TWI351288B (en) *	2008-07-04	2011-11-01	Univ Nat Pingtung Sci & Tech	Cpg dna adjuvant in avian vaccines
KR101707569B1 (ko)	2008-08-01	2017-02-16	감마 백신즈 피티와이 리미티드	인플루엔자 백신
JP2012503206A (ja)	2008-09-22	2012-02-02	オレゴンヘルスアンドサイエンスユニバーシティ	Ｍｙｃｏｂａｃｔｅｒｉｕｍｔｕｂｅｒｃｕｌｏｓｉｓ感染を検出するための方法
EP2349209A2 (de)	2008-09-26	2011-08-03	Nanobio Corporation	Therapeutische zusammensetzungen in nanoemulsionsform und anwendungsverfahren dafür
US8734803B2 (en)	2008-09-28	2014-05-27	Ibio Inc.	Humanized neuraminidase antibody and methods of use thereof
WO2010037408A1 (en)	2008-09-30	2010-04-08	Curevac Gmbh	Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
HUE028497T2 (en) *	2008-10-16	2016-12-28	The Univ Of Saskatchewan	Combination adjuvant composition
WO2010048572A1 (en)	2008-10-23	2010-04-29	Cornell University	A novel anti-viral method
WO2010048731A1 (en) *	2008-10-31	2010-05-06	Christopher John Ong	Aminoacyl trna-synthetase inhibitors as broad-spectrum immunosuppressive agents
WO2010057197A1 (en)	2008-11-17	2010-05-20	The Regents Of The University Of Michigan	Cancer vaccine compositions and methods of using the same
US9283184B2 (en)	2008-11-24	2016-03-15	Massachusetts Institute Of Technology	Methods and compositions for localized agent delivery
EP2370451B1 (de)	2008-12-02	2016-11-16	Wave Life Sciences Japan, Inc.	Verfahren zur synthese von am phosphoratom modifizierten nukleinsäuren
EP2356225A1 (de)	2008-12-03	2011-08-17	Protea Vaccine Technologies Ltd.	Glutamyl-trna-synthetase-(gts-)fragmente
JP2012510284A (ja)	2008-12-03	2012-05-10	プロイェクト、デ、ビオメディシナ、シーマ、ソシエダッド、リミターダ	ワクチンの開発のためのフェノール可溶性モジュリンの使用
NZ593220A (en)	2008-12-09	2012-10-26	Coley Pharm Group Inc	Immunostimulatory oligonucleotides
US8552165B2 (en)	2008-12-09	2013-10-08	Heather Davis	Immunostimulatory oligonucleotides
AU2009325950B2 (en)	2008-12-09	2013-03-07	Pfizer Vaccines Llc	IgE CH3 peptide vaccine
BRPI1005670A8 (pt)	2009-01-05	2017-12-26	Epitogenesis Inc	composições adjuvantes e processos de uso.
NZ593749A (en)	2009-01-20	2012-05-25	Transgene Sa	Soluble icam-1 as biomarker for prediction of therapeutic response
US20100234283A1 (en)	2009-02-04	2010-09-16	The Ohio State University Research Foundation	Immunogenic epitopes, peptidomimetics, and anti-peptide antibodies, and methods of their use
WO2010089340A2 (en)	2009-02-05	2010-08-12	Intercell Ag	Peptides protective against e. faecalis, methods and uses relating thereto
EP2405938A2 (de)	2009-02-13	2012-01-18	Intercell AG	Nicht typisierbare haemophilus influenza-antigene
US8664183B2 (en)	2009-02-27	2014-03-04	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	SPANX-B polypeptides and their use
WO2010105815A2 (en)	2009-03-17	2010-09-23	Oncomethylome Sciences S.A.	Improved detection of gene expression
ES2432863T3 (es)	2009-03-23	2013-12-05	Pin Pharma, Inc.	Tratamiento del cáncer con polipéptidos inmunoestimuladores derivados de Tat del VIH
DK2411815T3 (en)	2009-03-24	2015-11-30	Transgene Sa	Biomarker MONITORING OF PATIENTS
WO2010115118A2 (en)	2009-04-03	2010-10-07	Antigenics, Inc.	Methods for preparing and using multichaperone-antigen complexes
SI2419728T1 (sl)	2009-04-17	2014-03-31	Transgene Sa	Bio-označevalec za monitoring pacientov
MX2011011134A (es) *	2009-04-21	2012-01-31	Selecta Biosciences Inc	Agentes inmunonanoterapeuticos que proporcionan una respuesta sesgada hacia th1.
WO2010125480A1 (en)	2009-04-30	2010-11-04	Coley Pharmaceutical Group, Inc.	Pneumococcal vaccine and uses thereof
MX2011012599A (es)	2009-05-27	2012-04-19	Selecta Biosciences Inc	Compuestos polimericos de agentes inmunomoduladores.
SG176220A1 (en)	2009-05-27	2011-12-29	Glaxosmithkline Biolog Sa	Casb7439 constructs
AU2010256461B2 (en)	2009-06-05	2016-03-17	Access To Advanced Health Institute	Synthetic glucopyranosyl lipid adjuvants
JP6110140B2 (ja)	2009-06-16	2017-04-05	ザリージェンツオブザユニヴァシティオブミシガン	ナノエマルションワクチン
MA33449B1 (fr)	2009-06-24	2012-07-03	Glaxosmithkline Biolog Sa	Antigènes recombinants du vrs
JP5796011B2 (ja)	2009-06-24	2015-10-21	グラクソスミスクラインバイオロジカルズソシエテアノニム	ワクチン
IN2012DN00720A (de)	2009-07-06	2015-06-19	Ontorii Inc
WO2011003905A1 (en)	2009-07-10	2011-01-13	Transgene Sa	Biomarker for selecting patients and related methods
EP3988115A3 (de)	2009-07-15	2022-08-17	GlaxoSmithKline Biologicals S.A.	Rsv-f-proteinzusammensetzungen und verfahren zu ihrer herstellung
WO2011011519A1 (en)	2009-07-21	2011-01-27	Chimerix, Inc.	Compounds, compositions and methods for treating ocular conditions
CA2768346A1 (en) *	2009-07-30	2011-02-03	Pfizer Vaccines Llc	Antigenic tau peptides and uses thereof
US20110033515A1 (en) *	2009-08-04	2011-02-10	Rst Implanted Cell Technology	Tissue contacting material
GB0913681D0 (en)	2009-08-05	2009-09-16	Glaxosmithkline Biolog Sa	Immunogenic composition
GB0913680D0 (en)	2009-08-05	2009-09-16	Glaxosmithkline Biolog Sa	Immunogenic composition
WO2011025286A2 (ko)	2009-08-26	2011-03-03	주식회사 알엔에이	리포테이코익산 유래 당지질 및 이를 포함하는 조성물
WO2011026111A1 (en)	2009-08-31	2011-03-03	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Oral delivery of a vaccine to the large intestine to induce mucosal immunity
US20110053829A1 (en)	2009-09-03	2011-03-03	Curevac Gmbh	Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
ES2670576T3 (es)	2009-09-03	2018-05-31	Pfizer Vaccines Llc	Vacuna de PCSK9
CN102573886A (zh) *	2009-09-17	2012-07-11	相互制药公司	用抗病毒剂治疗哮喘的方法
GB0917457D0 (en)	2009-10-06	2009-11-18	Glaxosmithkline Biolog Sa	Method
WO2011041391A1 (en)	2009-09-29	2011-04-07	Fraunhofer Usa, Inc.	Influenza hemagglutinin antibodies, compositions, and related methods
AU2010305273B2 (en)	2009-10-07	2016-09-29	Uvic Industry Partnerships Inc.	Vaccines comprising heat-sensitive transgenes
EP2319871A1 (de)	2009-11-05	2011-05-11	Sanofi-aventis	Polypeptide zum Binden an den Rezeptor für weiterentwickelte Glykierungsendprodukte sowie Zusammensetzungen und Verfahren, die diese Polypeptide beinhalten
JP2013507115A (ja)	2009-10-09	2013-03-04	サノフイ	「終末糖化産物受容体」への結合のためのポリペプチド、さらにはそれを含む組成物及び方法
EP2308896A1 (de)	2009-10-09	2011-04-13	Sanofi-aventis	Polypeptides zum Binden an den Rezeptor für weiterentwickelte Glykierungsendprodukte sowie Zusammensetzungen und Verfahren, die diese Polypeptide beinhalten
US9181306B2 (en)	2009-10-16	2015-11-10	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Insertion of foreign genes in rubella virus and their stable expression in a live, attenuated viral vaccine
GB0919117D0 (en)	2009-10-30	2009-12-16	Glaxosmithkline Biolog Sa	Process
US8961989B2 (en)	2009-11-20	2015-02-24	Oregon Health & Science University	Methods for producing an immune response to tuberculosis
WO2011067758A2 (en)	2009-12-02	2011-06-09	Protea Vaccine Technologies Ltd.	Immunogenic fragments and multimers from streptococcus pneumoniae proteins
EP3257525A3 (de)	2009-12-22	2018-02-28	Celldex Therapeutics, Inc.	Impstoffe zusammensetzungen
FR2954703B1 (fr)	2009-12-28	2013-12-13	Chu Nantes	Agonistes des recepteurs tlr 4 et 9 pour prevenir les complications septiques de l'immunodepression post-traumatique chez les patients hospitalises pour traumatismes severes
PL2534150T3 (pl)	2010-02-12	2017-09-29	Chimerix, Inc.	Sposoby leczenia infekcji wirusowej
WO2011101332A1 (en)	2010-02-16	2011-08-25	Proyecto De Biomedicina Cima, S.L.	Compositions based on the fibronectin extracellular domain a for the treatment of melanoma
US8685416B2 (en)	2010-03-02	2014-04-01	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Compositions and methods for the treatment of cancer
CA2792258A1 (en)	2010-03-05	2011-09-09	President And Fellows Of Harvard College	Induced dendritic cell compositions and uses thereof
GB201003920D0 (en)	2010-03-09	2010-04-21	Glaxosmithkline Biolog Sa	Method of treatment
GB201003924D0 (en)	2010-03-09	2010-04-21	Glaxosmithkline Biolog Sa	Immunogenic composition
CN102869377A (zh)	2010-03-10	2013-01-09	葛兰素史密丝克莱恩生物有限公司	免疫原性组合物
WO2011112599A2 (en)	2010-03-12	2011-09-15	The United States Of America, As Represented By The Secretary. Department Of Health & Human Services	Immunogenic pote peptides and methods of use
US8747869B2 (en)	2010-03-19	2014-06-10	Massachusetts Institute Of Technology	Lipid vesicle compositions and methods of use
US9149432B2 (en)	2010-03-19	2015-10-06	Massachusetts Institute Of Technology	Lipid vesicle compositions and methods of use
US20110229556A1 (en) *	2010-03-19	2011-09-22	Massachusetts Institute Of Technology	Lipid-coated polymer particles for immune stimulation
GB201005005D0 (en) *	2010-03-25	2010-05-12	Angeletti P Ist Richerche Bio	New vaccine
TR201802933T4 (tr)	2010-03-30	2018-03-21	Childrens Hospital & Res Center At Oakland	Özellikleri değiştirilmiş faktör h bağlama proteinleri (fhbp) ve bunların kullanım yöntemi.
MX339621B (es)	2010-04-13	2016-06-02	Celldex Therapeutics Inc *	Anticuerpos que se unen a cd27 humano y uso de los mismos.
US9278135B2 (en)	2010-04-26	2016-03-08	Chimerix Inc.	Methods of treating retroviral infections and related dosage regimes
CA2798136C (en)	2010-05-14	2019-06-04	Oregon Health & Science University	Recombinant hcmv and rhcmv vectors and uses thereof
MX352324B (es)	2010-05-26	2017-11-17	Selecta Biosciences Inc Star	Vacunas multivalentes de nanovehiculos sinteticos.
EP2575878B1 (de) *	2010-05-28	2018-06-13	Zoetis Belgium S.A.	Impstoffe mit cholesterin und cpg als einzige adjuvans-träger moleküle
WO2011154878A1 (en)	2010-06-07	2011-12-15	Pfizer Vaccines Llc	Ige ch3 peptide vaccine
US8658603B2 (en)	2010-06-16	2014-02-25	The Regents Of The University Of Michigan	Compositions and methods for inducing an immune response
DK2449113T3 (en)	2010-07-30	2016-01-11	Curevac Ag	Complex formation of nucleic acids with the disulfide cross-linked cationic components for transfection and immunostimulation
CN103957931B (zh)	2010-09-03	2017-10-24	瓦尔内瓦奥地利有限责任公司	艰难梭状芽胞杆菌毒素a和毒素b蛋白的分离多肽及其用途
AR082925A1 (es)	2010-09-08	2013-01-16	Medigene Ag	Proteinas estructurales mutadas por parvovirus con epitopo de celulas b de proteccion cruzada, producto y metodos relacionados
GB201015132D0 (en)	2010-09-10	2010-10-27	Univ Bristol	Vaccine composition
WO2012036993A1 (en)	2010-09-14	2012-03-22	University Of Pittsburgh-Of The Commonwealth System Of Higher Education	Computationally optimized broadly reactive antigens for influenza
WO2012039448A1 (ja)	2010-09-24	2012-03-29	株式会社キラルジェン	不斉補助基
AU2011310838B2 (en)	2010-09-27	2015-11-05	Crucell Holland B.V.	Heterologous prime boost vaccination regimen against malaria
KR102157971B1 (ko)	2010-10-06	2020-09-18	프레지던트 앤드 펠로우즈 오브 하바드 칼리지	재료에 기초한 세포 치료를 위한 주사 가능한 기공 형성 하이드로겔
WO2012057904A1 (en)	2010-10-27	2012-05-03	Infectious Disease Research Institute	Mycobacterium tuberculosis antigens and combinations thereof having high seroreactivity
US9994443B2 (en)	2010-11-05	2018-06-12	Selecta Biosciences, Inc.	Modified nicotinic compounds and related methods
ES2859673T3 (es)	2010-11-08	2021-10-04	Infectious Disease Res Inst	Vacunas que comprenden polipéptidos de nucleósido hidrolasa no específica y esterol 24-c-metiltransferasa (SMT) para el tratamiento y el diagnóstico de la leishmaniasis
MX344280B (es)	2010-12-14	2016-12-09	Glaxosmithkline Biologicals Sa	Composicion antigenica de micobacteria.
WO2012100302A1 (en)	2011-01-27	2012-08-02	Gamma Vaccines Pty Limited	Combination vaccines
CN103517713A (zh)	2011-02-22	2014-01-15	彼昂德瓦克斯医药有限公司	在改善的季节性和大流行性流感疫苗中的多聚体多表位多肽
US20140004142A1 (en)	2011-03-02	2014-01-02	Pfizer Inc.	Pcsk9 vaccine
EP2505640A1 (de)	2011-03-29	2012-10-03	Neo Virnatech, S.L.	Impfstoffzusammensetzungen für vom Birnavirus übertragenen Krankheiten
GB201106357D0 (en)	2011-04-14	2011-06-01	Pessi Antonello	Composition and uses thereof
JP6054942B2 (ja)	2011-04-08	2016-12-27	イミューンデザインコーポレイション	免疫原性組成物、ならびに体液性および細胞性免疫応答を誘発するための該組成物の使用方法
TW201302779A (zh)	2011-04-13	2013-01-16	Glaxosmithkline Biolog Sa	融合蛋白質及組合疫苗
US20120288515A1 (en)	2011-04-27	2012-11-15	Immune Design Corp.	Synthetic long peptide (slp)-based vaccines
LT2707385T (lt)	2011-05-13	2017-12-11	Glaxosmithkline Biologicals Sa	Iš anksto sulieti rsv f antigenai
FR2975600B1 (fr)	2011-05-24	2013-07-05	Assist Publ Hopitaux De Paris	Agents pour le traitement de tumeurs
CN103717070A (zh)	2011-06-01	2014-04-09	贾纳斯生物治疗有限公司	新型免疫系统调节剂
AU2012262021B2 (en)	2011-06-01	2016-07-28	Janus Biotherapeutics, Inc.	Novel immune system modulators
EP2718292B1 (de)	2011-06-03	2018-03-14	3M Innovative Properties Company	Hydrazin-1h-imidazochinolin-4-amine und daraus hergestellte konjugate
JP6460789B2 (ja)	2011-06-03	2019-01-30	スリーエムイノベイティブプロパティズカンパニー	ポリエチレングリコールセグメントを有するヘテロ２官能性リンカー及び該リンカーから調製された免疫反応調節複合体
CA2838188C (en)	2011-06-04	2017-04-18	Rochester General Hospital Research Institute	Compositions and methods related to p6 of haemophilus influenzae
CN103906840B (zh)	2011-06-07	2018-01-30	艾比欧公司	重组蛋白通过与PNGase F共表达在活体内去糖基化
CN103648526A (zh)	2011-06-17	2014-03-19	田纳西大学研究基金会	A群链球菌多价疫苗
EP2721158B1 (de)	2011-06-20	2017-05-03	University of Pittsburgh - Of the Commonwealth System of Higher Education	Rechnerisch optimierte breit reaktive h1n1-influenza-antigene
CN103608030A (zh)	2011-06-21	2014-02-26	昂科发克特公司	用于治疗和诊断癌症的组合物和方法
WO2013007703A1 (en) *	2011-07-08	2013-01-17	Universität Zürich	CLASS A CpG OLIGONUCLEOTIDES FOR PREVENTION OF VIRAL INFECTION IN CATS
RU2014105311A (ru)	2011-07-19	2015-08-27	Уэйв Лайф Сайенсес Пте. Лтд.	Способы синтеза функционализованных нуклеиновых кислот
US20130023736A1 (en)	2011-07-21	2013-01-24	Stanley Dale Harpstead	Systems for drug delivery and monitoring
WO2013019648A1 (en)	2011-07-29	2013-02-07	Selecta Biosciences, Inc.	Control of antibody responses to synthetic nanocarriers
GB201114919D0 (en)	2011-08-30	2011-10-12	Glaxosmithkline Biolog Sa	Method
US20140348865A1 (en)	2011-09-12	2014-11-27	The United States Of America, As Represented By The Secretary, Department Of Health And Human Ser.	Immunogens based on an hiv-1 v1v2 site-of-vulnerability
WO2013038156A1 (en)	2011-09-16	2013-03-21	Ucb Pharma S.A.	Neutralising antibodies to the major exotoxins tcda and tcdb of clostridium difficile
ES2548391T3 (es)	2011-09-21	2015-10-16	Ruprecht-Karls-Universität Heidelberg	Péptidos de cambio de marco (FSP) específicos de MSI para prevención y tratamiento del cáncer
US20140234360A1 (en)	2011-09-30	2014-08-21	The United States of America, as represented by the Secretary, Dept.of Health and Human Services	Influenza vaccine
JP2014528449A (ja)	2011-10-04	2014-10-27	ジャナスバイオセラピューティクス，インク．	新規なイミダゾールキノリン系免疫系調節剤
US20140286983A1 (en)	2011-10-20	2014-09-25	The Government of the USA as represented by the Secretaryof the Dept. of Health and Human Services	Dengue virus e-glycoprotein polypeptides containing mutations that eliminate immunodominant cross-reactive epitopes
EP2780034A1 (de)	2011-11-14	2014-09-24	Crucell Holland B.V.	Heterologe prime-boost-impfung mit auf masernviren basierten impfstoffen
EP2596806A1 (de)	2011-11-25	2013-05-29	Index Pharmaceuticals AB	Verfahren zur Vorbeugung einer Dickdarmresektion
US9713630B2 (en)	2012-01-16	2017-07-25	Labyrinth Holdings, Llc	Compositions and methods for the treatment of hepatic diseases and disorders
WO2013113326A1 (en)	2012-01-31	2013-08-08	Curevac Gmbh	Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen
HUE044841T2 (hu)	2012-02-07	2019-11-28	Infectious Disease Res Inst	TLR4 agonistákat tartalmazó javított adjuváns készítmények és azok alkalmazási eljárásai
KR20140127827A (ko)	2012-02-07	2014-11-04	유니버시티 오브 피츠버그 - 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션	H3n2, h2n2, 및 b 인플루엔자 바이러스에 대한 계산적으로 최적화된 넓게 반응하는 항원
JP6175452B2 (ja)	2012-02-13	2017-08-02	ユニバーシティオブピッツバーグ − オブザコモンウェルスシステムオブハイヤーエデュケイション	ヒトおよびトリｈ５ｎ１インフルエンザのための、計算で最適化した反応性の広い抗原
WO2013142808A1 (en)	2012-03-23	2013-09-26	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Pathogenic phlebovirus isolates and compositions and methods of use
WO2013150518A1 (en)	2012-04-01	2013-10-10	Rappaport Family Institute For Research In The Medical Sciences	Extracellular matrix metalloproteinase inducer (emmprin) peptides and binding antibodies
EP3662896B1 (de)	2012-04-16	2024-02-28	President and Fellows of Harvard College	Mesoporöse siliciumdioxidzusammensetzungen zur modulierung von immunreaktionen
US9597385B2 (en)	2012-04-23	2017-03-21	Allertein Therapeutics, Llc	Nanoparticles for treatment of allergy
MX376235B (es)	2012-05-04	2025-03-07	Pfizer Inc	Antígenos asociados a próstata y regímenes de inmunoterapia basados en vacuna.
SMT201800368T1 (it)	2012-05-16	2018-09-13	Immune Design Corp	Vaccini per l'infezione da virus-2 herpes simplex
JP6216371B2 (ja)	2012-05-23	2017-10-18	ザユナイテッドステイツオブアメリカ，アズリプレゼンテッドバイザセクレタリー，デパートメントオブヘルスアンドヒューマンサービシーズ	ＹｅｒｓｉｎｉａｐｅｓｔｉｓＦ１−Ｖ融合タンパク質を発現するＳａｌｍｏｎｅｌｌａＴｙｐｈｉＴｙ２１ａおよびその使用
EP2666785A1 (de)	2012-05-23	2013-11-27	Affiris AG	Auf Komplementfaktor C5a basierender Impfstoff
WO2013177397A1 (en)	2012-05-24	2013-11-28	The United States Of America, As Represented By The Secretary, Department Of Health & Human Services	Multivalent meningococcal conjugates and methods for preparing cojugates
US9687542B2 (en)	2012-06-19	2017-06-27	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Rift valley fever virus replicon particles and use thereof
ES2940887T3 (es)	2012-07-13	2023-05-12	Wave Life Sciences Ltd	Método de preparación de oligonucleótidos quirales
EP2872485B1 (de)	2012-07-13	2020-12-16	Wave Life Sciences Ltd.	Asymmetrische hilfsgruppe
WO2014010718A1 (ja)	2012-07-13	2014-01-16	株式会社新日本科学	キラル核酸アジュバント
HRP20240164T1 (hr)	2012-08-03	2024-04-12	Access To Advanced Health Institute	Pripravci i postupci za liječenje aktivne tuberkulozne infekcije mikobakterijama
JP2015525794A (ja)	2012-08-06	2015-09-07	グラクソスミスクラインバイオロジカルズソシエテアノニム	乳児においてｒｓｖ及び百日咳菌に対する免疫応答を惹起するための方法
US20140037680A1 (en)	2012-08-06	2014-02-06	Glaxosmithkline Biologicals, S.A.	Novel method
WO2014031178A1 (en)	2012-08-24	2014-02-27	Etubics Corporation	Replication defective adenovirus vector in vaccination
EP2703483A1 (de)	2012-08-29	2014-03-05	Affiris AG	PCSK9 Peptidimpfstoff
US10973892B2 (en)	2012-09-04	2021-04-13	Bavarian Nordic A/S	Methods and compositions for enhancing vaccine immune responses
WO2014043535A1 (en)	2012-09-14	2014-03-20	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Compositions for the treatment of cancer
EP2895191B1 (de)	2012-09-14	2019-06-05	The U.S.A. as represented by the Secretary, Department of Health and Human Services	Brachyury-protein, adenovirale vektoren zur codierung von brachyury-protein und deren verwendung
US10232035B2 (en)	2012-09-14	2019-03-19	The Regents Of The University Of Colorado, A Body Corporate	Conditionally replication deficient herpes virus and use thereof in vaccines
WO2014047588A1 (en)	2012-09-21	2014-03-27	Elizabeth Mckenna	Naturally occurring cpg oligonucleotide compositions and therapeutic applications thereof
ES2854754T3 (es)	2012-10-24	2021-09-22	Platelet Targeted Therapeutics Llc	Tratamiento dirigido a plaquetas
KR101810840B1 (ko)	2012-12-13	2017-12-20	루프레히트-칼스-유니페어지테트 하이델베르크	암의 예방 및 치료용 msi-특이적 프레임쉬프트 펩티드(fsp)
HUE051988T2 (hu)	2013-01-07	2021-04-28	Univ Pennsylvania	Készítmények és eljárások bõr T-sejt lymphoma kezelésére
CA2936092A1 (en)	2013-01-23	2014-07-31	The Board Of Trustees Of The Leland Stanford Junior University	Stabilized hepatitis b core polypeptide
CN112851766A (zh)	2013-03-13	2021-05-28	美国政府(由卫生和人类服务部的部长所代表)	融合前rsv f蛋白和其用途
EP3608332B1 (de)	2013-03-15	2022-06-01	GlaxoSmithKline Biologicals SA	Impfstoff gegen humanes rhinovirus
EP2978447B1 (de)	2013-03-28	2019-05-08	Infectious Disease Research Institute	Impfstoffe mit leishmania-polypeptiden zur behandlung und diagnose von leishmaniase
EP2981285B1 (de)	2013-04-03	2020-06-03	N-Fold Llc	Neuartige nanopartikelzusammensetzungen
WO2014172637A1 (en)	2013-04-18	2014-10-23	Immune Design Corp.	Gla monotherapy for use in cancer treatment
CA2909721A1 (en)	2013-04-19	2014-10-23	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Lone star virus
WO2015132619A1 (en)	2013-05-15	2015-09-11	The Governors Of The University Of Alberta	E1e2 hcv vaccines and methods of use
US9463198B2 (en)	2013-06-04	2016-10-11	Infectious Disease Research Institute	Compositions and methods for reducing or preventing metastasis
GB201310008D0 (en)	2013-06-05	2013-07-17	Glaxosmithkline Biolog Sa	Immunogenic composition for use in therapy
WO2014201245A1 (en)	2013-06-12	2014-12-18	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Tlr-9 agonist with tlr-7 and/or tlr-8 agonist for treating tumors
AU2014292926B2 (en)	2013-07-25	2020-03-05	Exicure Operating Company	Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
WO2015011254A1 (en)	2013-07-26	2015-01-29	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for the treatment of bacterial infections
BR112016002354A2 (pt)	2013-08-05	2017-09-12	Glaxosmithkline Biologicals Sa	composição imunogênica, métodos para proteger um bebê contra infecção ou doença e para evocar uma resposta imune, regime de vacinação, e, kit
ES2747762T3 (es)	2013-08-21	2020-03-11	Curevac Ag	Vacuna contra el virus respiratorio sincitial (RSV)
EP4043036A1 (de)	2013-09-27	2022-08-17	Massachusetts Institute of Technology	Trägerfreie biologisch aktive proteinnanostrukturen
WO2015048785A2 (en)	2013-09-30	2015-04-02	Los Alamos National Security, Llc	Mosaic conserved region hiv immunogenic polypeptides
CA2926221A1 (en)	2013-10-04	2015-04-09	Pin Pharma, Inc.	Immunostimulatory hiv tat derivative polypeptides for use in cancer treatment
SG10201910889VA (en)	2013-11-01	2020-01-30	Pfizer	Vectors for expression of prostate-associated antigens
EP3063171B1 (de)	2013-11-01	2019-07-24	University Of Oslo	Albuminvarianten und verwendungen davon
WO2015070207A2 (en)	2013-11-11	2015-05-14	The Government Of The United States, As Represented By The Secretary Of The Army	Ama-1 epitopes, antibodies, compositions, and methods of making and using the same
EP3068426B1 (de)	2013-11-13	2020-02-12	University Of Oslo	Aussenmembranvesikel und verwendungen davon
EP3069138B1 (de)	2013-11-15	2019-01-09	Oslo Universitetssykehus HF	Ctl-peptid-epitope und antigen-spezifische t-zellen, verfahren zu deren entdeckung und verwendungen davon
WO2015077442A2 (en)	2013-11-20	2015-05-28	La Jolla Institute For Allergy And Immunology	Grass pollen immunogens and methods and uses for immune response modulation
US20160287696A1 (en)	2013-11-20	2016-10-06	La Jolla Institute For Allergy And Immunology	Pan pollen immunogens and methods and uses for immune response modulation
AU2014356546A1 (en)	2013-11-28	2016-06-02	Bavarian Nordic A/S	Compositions and methods vectors for inducing an enhanced immune response using poxvirus vectors
WO2015089469A1 (en)	2013-12-13	2015-06-18	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Multi-epitope tarp peptide vaccine and uses thereof
WO2015092710A1 (en)	2013-12-19	2015-06-25	Glaxosmithkline Biologicals, S.A.	Contralateral co-administration of vaccines
AU2014373928C1 (en)	2013-12-31	2020-12-17	Access To Advanced Health Institute	Single vial vaccine formulations
WO2015108048A1 (ja) *	2014-01-15	2015-07-23	株式会社新日本科学	抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
EP3095461A4 (de) *	2014-01-15	2017-08-23	Shin Nippon Biomedical Laboratories, Ltd.	Chirales nukleinsäure-adjuvans mit immunitätsinduktionswirkung und immunitätsinduktionsaktivator
JPWO2015108046A1 (ja) *	2014-01-15	2017-03-23	株式会社新日本科学	抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤
KR20240164968A (ko)	2014-01-16	2024-11-21	웨이브 라이프 사이언시스 리미티드	키랄 디자인
PL3096783T3 (pl)	2014-01-21	2021-12-13	Pfizer Inc.	Polisacharydy otoczkowe streptococcus pneumoniae i ich koniugaty
RU2771293C2 (ru)	2014-01-21	2022-04-29	Пфайзер Инк.	Иммуногенные композиции, содержащие конъюгированные капсульные сахаридные антигены, и их применение
MX371453B (es)	2014-01-21	2020-01-29	Pfizer	Polisacaridos capsulares de streptococcus pneumoniae y conjugados de los mismos.
US11160855B2 (en)	2014-01-21	2021-11-02	Pfizer Inc.	Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
MX2016009464A (es)	2014-01-21	2017-01-16	Immune Design Corp	Composiciones para el uso en el tratamiento de afecciones alergicas.
EP3104877B1 (de)	2014-02-11	2020-01-22	The USA, as represented by The Secretary, Department of Health and Human Services	Pcsk9-impfstoff und verfahren zur verwendung davon
TW201620927A (zh)	2014-02-24	2016-06-16	葛蘭素史密斯克藍生物品公司	Ｕｓｐａ２蛋白質構築體及其用途
WO2015131053A1 (en)	2014-02-28	2015-09-03	Alk-Abelló A/S	Polypeptides derived from phl p and methods and uses thereof for immune response modulation
US10369216B2 (en)	2014-04-01	2019-08-06	Curevac Ag	Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant
US10111948B2 (en)	2014-04-25	2018-10-30	Tria Bioscience Corp.	Synthetic hapten carrier compositions and methods
EP3137105A4 (de)	2014-04-30	2017-12-27	President and Fellows of Harvard College	Kombinationsimpfstoffvorrichtungen und -verfahren zur abtötung von krebszellen
CA2986096A1 (en)	2014-05-30	2015-12-03	Sanofi Pasteur Inc.	Expression and conformational analysis of engineered influenza hemagglutinin
CN106535876B (zh)	2014-06-04	2020-09-11	埃克西奎雷股份有限公司	免疫调节剂通过脂质体球形核酸的多价递送以用于预防或治疗应用
EP2952893A1 (de)	2014-06-04	2015-12-09	Institut d'Investigació Biomèdica de Bellvitge (IDIBELL)	Verfahren zur Erkennung von antikörpersezernierenden, HLA-spezifischen B-Zellen
EP3154576A1 (de)	2014-06-13	2017-04-19	GlaxoSmithKline Biologicals S.A.	Immunogene kombinationen
JP2017522312A (ja)	2014-07-15	2017-08-10	イミューンデザインコーポレイション	Ｔｌｒ４アゴニストアジュバント及びレンチウイルスベクターを用いたプライム・ブーストレジメン
EP3169699A4 (de)	2014-07-18	2018-06-20	The University of Washington	Krebsimpfstoffzusammensetzungen und verfahren zur verwendung davon
WO2016012385A1 (en)	2014-07-21	2016-01-28	Sanofi Pasteur	Vaccine composition comprising ipv and cyclodextrins
CN107108629A (zh)	2014-08-22	2017-08-29	贾纳斯生物治疗有限公司	新颖的n2, n4, n7, 6‑四取代的蝶啶‑2,4,7‑三胺和2, 4, 6, 7‑四取代的蝶啶化合物及其合成和使用方法
SG11201702656WA (en)	2014-10-06	2017-04-27	Exicure Inc	Anti-tnf compounds
ES2924988T3 (es)	2014-10-10	2022-10-13	Univ Michigan Regents	Composiciones con nanoemulsiones para prevenir, inhibir o eliminar una enfermedad alérgica e inflamatoria
AU2015252119A1 (en)	2014-11-07	2016-05-26	Takeda Vaccines, Inc.	Hand, foot, and mouth vaccines and methods of manufacture and use thereof
AR102547A1 (es)	2014-11-07	2017-03-08	Takeda Vaccines Inc	Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso
US11213593B2 (en)	2014-11-21	2022-01-04	Northwestern University	Sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
MX2017007652A (es)	2014-12-10	2017-10-11	Glaxosmithkline Biologicals Sa	Metodo de tratamiento.
PL3233912T3 (pl)	2014-12-19	2021-12-27	Regenesance B.V.	Przeciwciała, które wiążą ludzkie c6 oraz ich zastosowania
LT3240801T (lt)	2014-12-31	2021-02-25	Checkmate Pharmaceuticals, Inc.	Kombinuota navikų imunoterapija
WO2016112195A1 (en)	2015-01-09	2016-07-14	Etubics Corporation	Methods and compositions for combination immunotherapy
MX2017009308A (es)	2015-01-15	2017-11-08	Pfizer	Composiciones inmunogenicas para usar en vacunas neumococicas.
CA3012602A1 (en)	2015-01-30	2016-08-04	President And Fellows Of Harvard College	Peritumoral and intratumoral materials for cancer therapy
US20180036334A1 (en)	2015-02-13	2018-02-08	Icahn School Of Medicine At Mount Sinai	Rna containing compositions and methods of their use
AU2015384786B2 (en)	2015-03-03	2020-08-27	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Display platform from bacterial spore coat proteins
CN107530416A (zh)	2015-03-05	2018-01-02	西北大学	非神经侵染的病毒及其用途
US20180044429A1 (en)	2015-03-09	2018-02-15	Celldex Therapeutics, Inc.	Cd27 agonists
US20180071380A1 (en)	2015-03-20	2018-03-15	The Regents Of The University Of Michigan	Immunogenic compositions for use in vaccination against bordetella
JP6903046B2 (ja)	2015-03-26	2021-07-14	ジーピーエヌワクチンプロプライアタリーリミティド	連鎖球菌ワクチン
US11150242B2 (en)	2015-04-10	2021-10-19	President And Fellows Of Harvard College	Immune cell trapping devices and methods for making and using the same
US11149087B2 (en)	2015-04-20	2021-10-19	Etubics Corporation	Methods and compositions for combination immunotherapy
WO2016180852A1 (en)	2015-05-12	2016-11-17	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for preparing antigen-specific t cells from an umbilical cord blood sample
JP6925980B2 (ja)	2015-05-13	2021-08-25	アジェナスインコーポレイテッド	がんの処置および予防のためのワクチン
BR112017025316A2 (pt)	2015-05-26	2018-07-31	Ohio State Innovation Foundation	estratégia de vacina baseada em nanopartículas contra o vírus da gripe suína
CA2987939A1 (en)	2015-06-02	2016-12-08	Sanofi Pasteur Inc.	Engineered influenza antigenic polypeptides and immunogenic compositions thereof
WO2016201224A1 (en)	2015-06-10	2016-12-15	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Processes for production and purification of nucleic acid-containing compositions
JP2018518511A (ja) *	2015-06-26	2018-07-12	バイエル・アニマル・ヘルス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒＡｎｉｍａｌＨｅａｌｔｈＧｍｂｈ	細胞質ｄｎａ監視分子の調節方法
TWI720448B (zh)	2015-07-21	2021-03-01	美商輝瑞股份有限公司	包含經共軛之莢膜糖抗原的致免疫性組成物、包含該致免疫性組成物之套組及彼等之用途
CN108990413A (zh)	2015-08-12	2018-12-11	麻省理工学院	纳米颗粒的细胞表面偶联
JP7223989B2 (ja)	2015-08-25	2023-02-17	アグラワル，バビタ	免疫調節組成物およびその使用方法
CN108024914A (zh)	2015-09-17	2018-05-11	Jrx生物技术有限公司	改善皮肤的水合作用或润湿作用的方法
US10526309B2 (en)	2015-10-02	2020-01-07	The University Of North Carolina At Chapel Hill	Pan-TAM inhibitors and Mer/Axl dual inhibitors
US10548970B2 (en)	2015-10-05	2020-02-04	The United States Of America, As Represented By The Secretary, Department Of Health & Human Services	Human rotavirus G9P[6] strain and use as a vaccine
CA3000313A1 (en)	2015-10-08	2017-04-13	The Governors Of The University Of Alberta	Hepatitis c virus e1/e2 heterodimers and methods of producing same
GB201518668D0 (en)	2015-10-21	2015-12-02	Glaxosmithkline Biolog Sa	Immunogenic Comosition
JP7171433B2 (ja)	2015-10-30	2022-11-15	ザユナイテッドステイツオブアメリカ，アズリプレゼンテッドバイザセクレタリー，デパートメントオブヘルスアンドヒューマンサービシーズ	Ｈｅｒ－２発現固形腫瘍の処置のための組成物および方法
WO2017085586A1 (en)	2015-11-20	2017-05-26	Pfizer Inc.	Immunogenic compositions for use in pneumococcal vaccines
WO2017120504A1 (en)	2016-01-08	2017-07-13	Durfee Paul N	Osteotropic nanoparticles for prevention or treatment of bone metastases
ES2921605T3 (es)	2016-01-29	2022-08-30	Bavarian Nordic As	Vacuna contra el virus de la encefalitis equina basada en el virus de la variolovacuna modificado Ankara (VMA) recombinante
CN115531609A (zh)	2016-02-06	2022-12-30	哈佛学院校长同事会	重塑造血巢以重建免疫
CA3017356A1 (en)	2016-03-10	2017-09-14	Aperisys, Inc.	Antigen-binding fusion proteins with modified hsp70 domains
CN109071631B (zh)	2016-03-14	2023-07-14	奥斯陆大学	具有改变的FcRn结合的工程化免疫球蛋白
WO2017158421A1 (en)	2016-03-14	2017-09-21	University Of Oslo	Anti-viral engineered immunoglobulins
EP3436066A1 (de)	2016-04-01	2019-02-06	Checkmate Pharmaceuticals, Inc.	Fc-rezeptor-vermittelte wirkstofffreisetzung
CN116059351A (zh)	2016-04-18	2023-05-05	塞德斯医疗公司	结合人cd40的激动性抗体及其用途
WO2017189448A1 (en)	2016-04-25	2017-11-02	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Bivalent immunogenic conjugate for malaria and typhoid
EP3458475B1 (de)	2016-05-16	2022-07-27	Access to Advanced Health Institute	Formulierung mit tlr-agonist und verfahren zur verwendung
WO2017201390A1 (en)	2016-05-19	2017-11-23	The Regents Of The University Of Michigan	Novel adjuvant compositions
MX2018014270A (es)	2016-05-21	2019-02-14	Infectious Disease Res Inst	Composiciones y metodos para tratar la tuberculosis secundaria e infecciones po micobacteria no tuberculosa.
KR20190034504A (ko)	2016-05-27	2019-04-02	이투빅스 코포레이션	네오에피토프 백신 조성물 및 이의 사용 방법
CN109195587A (zh)	2016-06-01	2019-01-11	传染病研究所	含上胶剂的纳米明矾颗粒
MA45165A (fr)	2016-06-02	2019-04-10	Sanofi Pasteur Inc	Polypeptides antigéniques de la grippe modifiés et compositions immunogéniques associées
AU2017275663B2 (en)	2016-06-03	2021-12-09	Sanofi Pasteur Inc.	Modification of engineered influenza hemagglutinin polypeptides
JP7185530B2 (ja)	2016-06-13	2022-12-07	トルクセラピューティクス，インコーポレイテッド	免疫細胞機能を促進するための方法および組成物
EP3468590B1 (de)	2016-06-13	2025-01-01	The United States of America, as represented by the Secretary, Department of Health and Human Services	Nukleinsäuren zur codierung von zika-virus-ähnlichen partikeln und deren verwendung in zika-virus-impfstoffen und diagnostischen tests
GB201610599D0 (en)	2016-06-17	2016-08-03	Glaxosmithkline Biologicals Sa	Immunogenic Composition
WO2017221072A2 (en)	2016-06-21	2017-12-28	University Of Oslo	Hla binding vaccine moieties and uses thereof
CA3030154A1 (en)	2016-07-08	2018-01-11	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Chimeric dengue/zika viruses live-attenuated zika virus vaccines
US10632185B2 (en)	2016-07-08	2020-04-28	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Chimeric west nile/zika viruses and methods of use
US11555177B2 (en)	2016-07-13	2023-01-17	President And Fellows Of Harvard College	Antigen-presenting cell-mimetic scaffolds and methods for making and using the same
EP3493837B1 (de)	2016-08-05	2022-08-31	Sanofi Pasteur, Inc.	Polyvalente pneumokokken-polysaccharid-proteinkonjugatzusammensetzung
SG11201900789VA (en)	2016-08-05	2019-02-27	Sanofi Pasteur Inc	Multivalent pneumococcal polysaccharide-protein conjugate composition
BR112019003462A2 (pt)	2016-08-23	2019-06-25	Glaxosmithkline Biologicals Sa	proteína de fusão, polinucleotídeo, vetor viral, composição farmacêutica, uso de uma proteína de fusão, polinucleotídeo, vetor viral ou composição farmacêutica, e, método para tratar ou prevenir infecção de hepatite b viral ou infecção de hepatite c viral
US11364304B2 (en)	2016-08-25	2022-06-21	Northwestern University	Crosslinked micellar spherical nucleic acids
US11801290B2 (en)	2016-09-16	2023-10-31	Access To Advanced Health Institute	Vaccines comprising Mycobacterium leprae polypeptides for the prevention, treatment, and diagnosis of leprosy
BE1024774B1 (fr)	2016-09-29	2018-07-02	Glaxosmithkline Biologicals Sa	Compositions et procedes de traitement
AU2017339576A1 (en) *	2016-10-07	2019-05-02	Secarna Pharmaceuticals Gmbh & Co. Kg	Immunosuppression-reverting oligonucleotides inhibiting the expression of CD39
US10172933B2 (en)	2016-10-31	2019-01-08	The United States Of America, As Represented By The Secretary Of Agriculture	Mosaic vaccines for serotype a foot-and-mouth disease virus
WO2018096396A1 (en)	2016-11-22	2018-05-31	University Of Oslo	Albumin variants and uses thereof
GB201620968D0 (en)	2016-12-09	2017-01-25	Glaxosmithkline Biologicals Sa	Adenovirus polynucleotides and polypeptides
US11084850B2 (en)	2016-12-16	2021-08-10	The Pirbright Institute	Recombinant prefusion RSV F proteins and uses thereof
BR112019014833A2 (pt)	2017-01-20	2020-04-14	Pfizer	composições imunogênicas para uso em vacinas pneumococais
WO2018160865A1 (en)	2017-03-01	2018-09-07	Charles Jeffrey Brinker	Active targeting of cells by monosized protocells
WO2018162450A1 (en)	2017-03-06	2018-09-13	Fundación Para La Investigación Médica Aplicada	New inmunostimulatory compositions comprising an entity of cold inducible rna-binding protein with an antigen for the activation of dendritic cells
US11167022B2 (en)	2017-03-31	2021-11-09	Glaxosmithkline Intellectual Property Development Limited	Immunogenic composition, use and method of treatment
WO2018178265A1 (en)	2017-03-31	2018-10-04	Glaxosmithkline Intellectual Property Development Limited	Immunogenic composition, use and method of treatment
UA129243C2 (uk)	2017-04-19	2025-02-26	Інстітьют Фо Рісьорч Ін Біомедцін	Антитіло, що зв'язується зі спорозоїтами p. falciparum
WO2018201090A1 (en)	2017-04-28	2018-11-01	Exicure, Inc.	Synthesis of spherical nucleic acids using lipophilic moieties
WO2018231706A1 (en)	2017-06-11	2018-12-20	Molecular Express, Inc.	Methods and compositions for substance use disorder vaccine formulations and uses thereof
CA3067224A1 (en)	2017-06-15	2018-12-20	Infectious Disease Research Institute	Nanostructured lipid carriers and stable emulsions and uses thereof
US11464845B2 (en)	2017-07-21	2022-10-11	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Neisseria meningitidis immunogenic compositions
US11723966B2 (en)	2017-08-14	2023-08-15	Glaxosmithkline Biologicals Sa	Methods of boosting immune responses
WO2019035963A1 (en)	2017-08-16	2019-02-21	Ohio State Innovation Foundation	NANOPARTICLE COMPOSITIONS FOR VACCINES AGAINST SALMONELLA
JP7285828B2 (ja)	2017-09-05	2023-06-02	トルクセラピューティクス，インコーポレイテッド	治療用タンパク質組成物ならびにその作製および使用方法
WO2019048936A1 (en)	2017-09-07	2019-03-14	University Of Oslo	VACCINE MOLECULES
EP3678698A1 (de)	2017-09-07	2020-07-15	University Of Oslo	Impfstoffmoleküle
AU2018330494A1 (en)	2017-09-08	2020-03-26	Mina Therapeutics Limited	HNF4a saRNA compositions and methods of use
WO2019051149A1 (en)	2017-09-08	2019-03-14	Infectious Disease Research Institute	LIPOSOMAL FORMULATIONS COMPRISING SAPONIN AND METHODS OF USE
US12036257B2 (en)	2017-10-31	2024-07-16	Kalivir Immunotherapeutics, Inc.	Platform oncolytic vector for systemic delivery
US11478541B2 (en)	2017-11-03	2022-10-25	Takeda Vaccines, Inc.	Method for inactivating Zika virus and for determining the completeness of inactivation
US11235046B2 (en)	2017-11-04	2022-02-01	Nevada Research & Innovation Corporation	Immunogenic conjugates and methods of use thereof
SG11202004773SA (en) *	2017-12-15	2020-06-29	Bayer Animal Health Gmbh	Immunostimulatory compositions
US11116830B2 (en)	2017-12-18	2021-09-14	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Bacterial polysaccharide-conjugated carrier proteins and use thereof
EP3727447A1 (de)	2017-12-19	2020-10-28	Massachusetts Institute of Technology	Reagenzien zur kopplung von antigen-adjuvans und verfahren zur verwendung
GB201721576D0 (en)	2017-12-21	2018-02-07	Glaxosmithkline Biologicals Sa	Hla antigens and glycoconjugates thereof
GB201721582D0 (en)	2017-12-21	2018-02-07	Glaxosmithkline Biologicals Sa	S aureus antigens and immunogenic compositions
US11369675B2 (en)	2018-01-22	2022-06-28	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Broadly protective inactivated influenza virus vaccine
EP3743102A1 (de)	2018-01-26	2020-12-02	Nantcell, Inc.	Zusammensetzungen und verfahren zur kombination eines krebsimpfstoffs und einer immunologischen adjuvanten therapie
EP3752194A4 (de)	2018-02-13	2022-03-16	Checkmate Pharmaceuticals, Inc.	Zusammensetzungen und verfahren für die tumorimmuntherapie
AU2019220386A1 (en)	2018-02-16	2020-08-20	2A Pharma Ab	Parvovirus structural protein for the treatment of autoimmune diseases
EP3527223A1 (de)	2018-02-16	2019-08-21	2A Pharma AB	Mutiertes parvovirus-strukturprotein
MX2020008455A (es)	2018-02-28	2021-10-26	Pfizer	Variantes de il-15 y usos de las mismas.
US11633471B2 (en)	2018-03-06	2023-04-25	Unm Rainforest Innovations	Compositions and methods for reducing serum triglycerides
US11576964B2 (en)	2018-03-28	2023-02-14	Sanofi Pasteur Inc.	Methods of generating broadly protective vaccine compositions comprising hemagglutinin
CA3095174A1 (en)	2018-04-03	2019-10-10	Sanofi	Antigenic ospa polypeptides
WO2019195291A1 (en)	2018-04-03	2019-10-10	Sanofi	Antigenic respiratory syncytial virus polypeptides
EP3773708A2 (de)	2018-04-03	2021-02-17	Sanofi	Antigene epstein-barr-virus-polypeptide
CN112512565A (zh)	2018-04-03	2021-03-16	赛诺菲	抗原性流感-铁蛋白多肽
CN112512564A (zh)	2018-04-03	2021-03-16	赛诺菲	铁蛋白蛋白
JP7511478B2 (ja)	2018-04-09	2024-07-05	チェックメイトファーマシューティカルズ	ウイルス様粒子中へのオリゴヌクレオチドのパッケージ化
SG11202010011RA (en)	2018-04-17	2020-11-27	Celldex Therapeutics Inc	Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs
SG11202010580TA (en)	2018-05-23	2020-12-30	Pfizer	Antibodies specific for cd3 and uses thereof
JP7057843B2 (ja)	2018-05-23	2022-04-20	ファイザー・インク	ＧＵＣＹ２ｃに特異的な抗体及びその使用
JP2021526831A (ja)	2018-06-12	2021-10-11	グラクソスミスクラインバイオロジカルズソシエテアノニム	アデノウイルスポリヌクレオチド及びポリペプチド
WO2020014656A1 (en)	2018-07-13	2020-01-16	University Of Georgia Research Foundation	Broadly reactive immunogens of influenza h3 virus, compositions and methods of use thereof
MX2021000548A (es)	2018-07-19	2021-07-02	Glaxosmithkline Biologicals Sa	Procesos para preparar polisacáridos en seco.
CN112601545A (zh)	2018-08-07	2021-04-02	葛兰素史密丝克莱恩生物有限公司	工艺和疫苗
US11260119B2 (en)	2018-08-24	2022-03-01	Pfizer Inc.	Escherichia coli compositions and methods thereof
CN111315407B (zh)	2018-09-11	2023-05-02	上海市公共卫生临床中心	一种广谱抗流感疫苗免疫原及其应用
WO2020061129A1 (en)	2018-09-19	2020-03-26	President And Fellows Of Harvard College	Compositions and methods for labeling and modulation of cells in vitro and in vivo
WO2020068798A1 (en)	2018-09-24	2020-04-02	Guo Jimin	Living mammalian cells modified with functional modular nanoparticles
WO2020117590A1 (en)	2018-12-04	2020-06-11	The Rockefeller University	Hiv vaccine immunogens
WO2020115171A1 (en)	2018-12-06	2020-06-11	Glaxosmithkline Biologicals Sa	Immunogenic compositions
US20220054632A1 (en)	2018-12-12	2022-02-24	Glaxosmithkline Biologicals Sa	Modified carrier proteins for o-linked glycosylation
US20220023413A1 (en)	2018-12-12	2022-01-27	The U.S.A., As Represented By The Secretary, Department Of Health And Human Services	Recombinant mumps virus vaccine expressing genotype g fusion and hemagglutinin-neuraminidase proteins
WO2020121159A1 (en)	2018-12-12	2020-06-18	Pfizer Inc.	Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
US20220023410A1 (en)	2018-12-14	2022-01-27	University Of Georgia Research Foundation, Inc.	Crimean-congo hemorrhagic fever virus replicon particles and use thereof
US20220370606A1 (en)	2018-12-21	2022-11-24	Pfizer Inc.	Combination Treatments Of Cancer Comprising A TLR Agonist
WO2020128012A1 (en)	2018-12-21	2020-06-25	Glaxosmithkline Biologicals Sa	Methods of inducing an immune response
GB201901608D0 (en)	2019-02-06	2019-03-27	Vib Vzw	Vaccine adjuvant conjugates
WO2020176716A1 (en)	2019-02-28	2020-09-03	Brinker C Jeffrey	Modular metal–organic polyhedra superassembly compositions
CN114957407A (zh)	2019-04-02	2022-08-30	赛诺菲	抗原性多聚呼吸道合胞病毒多肽
EP3952906A1 (de)	2019-04-10	2022-02-16	Pfizer Inc.	Immunogene zusammensetzungen mit konjugierten kapselförmigen saccharidantigenen, kits damit und verwendungen davon
US20220221455A1 (en)	2019-04-18	2022-07-14	Glaxosmithkline Biologicals Sa	Antigen binding proteins and assays
EP3972639A1 (de)	2019-05-20	2022-03-30	Valneva SE	Subunit-impfstoff zur behandlung oder vorbeugung einer atemwegsinfektion
MX2021014363A (es)	2019-05-25	2022-02-21	Infectious Disease Res Inst	Composicion y metodo para secar por pulverizacion una emulsion de vacuna adyuvante.
US12214028B2 (en)	2019-05-31	2025-02-04	Universidad De Chile	Immunogenic formulation that induces protection against shiga toxin-producing Escherichia coli (STEC)
EP3770269A1 (de)	2019-07-23	2021-01-27	GlaxoSmithKline Biologicals S.A.	Quantifizierung von biokonjugatglykosylierung
AU2020325645A1 (en)	2019-08-05	2022-02-17	Glaxosmithkline Biologicals Sa	Immunogenic composition
WO2021042022A1 (en)	2019-08-30	2021-03-04	University Of Rochester	Septin inhibitors for treatment of cancers
US20230020894A1 (en)	2019-09-18	2023-01-19	Children's Medical Center Corporation	An anaplastic lymphoma kinase (alk) cancer vaccine and methods of use
EP3799884A1 (de)	2019-10-01	2021-04-07	GlaxoSmithKline Biologicals S.A.	Immunogene zusammensetzungen
CN114667343A (zh)	2019-11-01	2022-06-24	辉瑞大药厂	大肠杆菌组合物及其方法
EP4058581A1 (de)	2019-11-15	2022-09-21	Infectious Disease Research Institute	Rig-i-agonist und adjuvans-formulierung zur tumorbehandlung
CN114728051A (zh)	2019-11-22	2022-07-08	葛兰素史克生物有限公司	细菌糖糖缀合物疫苗的剂量和施用
IL293926A (en)	2019-12-17	2022-08-01	Pfizer	Antibodies specific for cd47, pd-l1, and uses thereof
BR112022010228A2 (pt)	2019-12-17	2022-09-06	Us Health	Vacinas de parasita de leishmania viva atenuada com características de segurança aumentadas
PE20230170A1 (es)	2020-02-23	2023-02-01	Pfizer	Composiciones de escherichia coli y sus metodos
EP4110382A1 (de)	2020-02-28	2023-01-04	Sanofi Pasteur Inc.	Hochdosierter influenzaimpfstoff für pädiatrische patienten
US11213482B1 (en)	2020-03-05	2022-01-04	University of Pittsburgh—Of the Commonwealth System of Higher Educat	SARS-CoV-2 subunit vaccine and microneedle array delivery system
MX2022013152A (es)	2020-04-20	2023-02-09	Univ Saskatchewan	Composiciones y métodos para prevenir, controlar y diagnosticar infecciones por micobacterias.
CA3189590A1 (en)	2020-07-17	2022-01-20	Pfizer Inc.	Therapeutic antibodies and their uses
JP7407081B2 (ja)	2020-07-20	2023-12-28	三菱重工機械システム株式会社	印刷機および印刷機の後片付け方法
AU2021337493A1 (en)	2020-09-04	2023-05-18	Access To Advanced Health Institute	Co-lyophilized rna and nanostructured lipid carrier
WO2022066973A1 (en)	2020-09-24	2022-03-31	Fred Hutchinson Cancer Research Center	Immunotherapy targeting pbk or oip5 antigens
CN116724053A (zh)	2020-09-24	2023-09-08	弗雷德哈钦森癌症中心	靶向sox2抗原的免疫治疗
WO2022074061A1 (en)	2020-10-07	2022-04-14	Valneva Sweden Ab	Cholera vaccine formulation
WO2022083760A1 (zh)	2020-10-23	2022-04-28	江苏省疾病预防控制中心(江苏省公共卫生研究院)	融合蛋白及其应用
US12138302B2 (en)	2020-10-27	2024-11-12	Pfizer Inc.	Escherichia coli compositions and methods thereof
MX2023004912A (es)	2020-10-27	2023-05-16	Pfizer	Composiciones de escherichia coli y metodos de las mismas.
CA3200602A1 (en)	2020-11-04	2022-05-12	Pfizer Inc.	Immunogenic compositions for use in pneumococcal vaccines
US20230405137A1 (en)	2020-11-10	2023-12-21	Pfizer Inc.	Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2022136952A1 (en)	2020-12-23	2022-06-30	Infectious Disease Research Institute	Solanesol vaccine adjuvants and methods of preparing same
US20220202923A1 (en)	2020-12-23	2022-06-30	Pfizer Inc.	E. coli fimh mutants and uses thereof
WO2022147373A1 (en)	2020-12-31	2022-07-07	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Antibody-guided pcsk9-mimicking immunogens lacking 9-residue sequence overlap with human proteins
WO2022175423A1 (en)	2021-02-22	2022-08-25	Glaxosmithkline Biologicals Sa	Immunogenic composition, use and methods
US20240156935A1 (en)	2021-03-31	2024-05-16	Vib Vzw	Vaccine Compositions for Trypanosomatids
KR20240006541A (ko)	2021-04-09	2024-01-15	셀덱스 쎄라퓨틱스, 인크.	Ilt4에 대한 항체, 이중특이적 항-ilt4/pd-l1 항체 및 이의 용도
AU2022255923A1 (en)	2021-04-09	2023-08-31	Valneva Se	Human metapneumo virus vaccine
CA3215344A1 (en)	2021-04-30	2022-11-03	Kalivir Immunotherapeutics, Inc.	Oncolytic viruses for modified mhc expression
JP2024521847A (ja)	2021-05-28	2024-06-04	ファイザー・インク	コンジュゲート化莢膜糖抗原を含む免疫原性組成物およびその使用
PH12023553205A1 (en)	2021-05-28	2024-02-19	Pfizer	Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
EP4370152A1 (de)	2021-07-16	2024-05-22	The Board Of Trustees Of The University Of Illinois	Universeller impfstoff für influenzavirus auf basis von tetramerem m2-protein in nanoscheiben
EP4384534A1 (de)	2021-08-11	2024-06-19	Sanofi Pasteur, Inc.	Verkürzte influenza-neuraminidase und verfahren zur verwendung davon
CA3233926A1 (en)	2021-10-08	2023-04-13	Sanofi Pasteur Inc.	Multivalent influenza vaccines
MX2024005462A (es)	2021-11-05	2024-05-22	Sanofi Sa	Vacuna de arn del virus respiratorio sincitial.
CN118302190A (zh)	2021-11-05	2024-07-05	赛诺菲	包含血凝素和神经氨酸酶的杂合多价流感疫苗及其使用方法
KR20240105412A (ko)	2021-11-05	2024-07-05	사노피 파스퇴르 인크	재조합 헤마글루티닌과 뉴라미니다제를 포함하는 다가 인플루엔자 백신 및 이의 사용 방법
WO2023077521A1 (en)	2021-11-08	2023-05-11	Celldex Therapeutics, Inc	Anti-ilt4 and anti-pd-1 bispecific constructs
WO2023083964A1 (en)	2021-11-11	2023-05-19	2A Pharma Ab	Parvovirus structural protein against beta- and gamma-hpv
CN118302191A (zh)	2021-11-30	2024-07-05	圣诺菲·帕斯图尔公司	基于病毒载体的人偏肺病毒疫苗
CA3239417A1 (en)	2021-11-30	2023-06-08	Yvonne CHAN	Human metapneumovirus vaccines
WO2023114727A1 (en)	2021-12-13	2023-06-22	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Bacteriophage lambda-vaccine system
EP4448103A1 (de)	2021-12-17	2024-10-23	Sanofi	Rna-impfstoff gegen lyme-krankheit
EP4463186A1 (de)	2022-01-13	2024-11-20	Pfizer Inc.	Immunogene zusammensetzungen mit konjugierten kapselsaccharidantigenen und verwendungen davon
CN118591621A (zh)	2022-01-27	2024-09-03	赛诺菲巴斯德有限公司	修饰的Vero细胞及其用于病毒生产的方法
WO2023161817A1 (en)	2022-02-25	2023-08-31	Pfizer Inc.	Methods for incorporating azido groups in bacterial capsular polysaccharides
CN119137665A (zh)	2022-03-14	2024-12-13	赛诺菲巴斯德有限公司	用于疫苗产生的蛋白质设计中的机器学习技术
AU2023265481A1 (en)	2022-05-06	2024-12-19	Sanofi	Signal sequences for nucleic acid vaccines
KR20250008122A (ko)	2022-05-11	2025-01-14	화이자 인코포레이티드	보존제를 갖는 백신 제형의 제조 방법
WO2023232901A1 (en)	2022-06-01	2023-12-07	Valneva Austria Gmbh	Clostridium difficile vaccine
WO2024003239A1 (en)	2022-06-29	2024-01-04	Bavarian Nordic A/S	RECOMBINANT MODIFIED saRNA (VRP) AND VACCINIA VIRUS ANKARA (MVA) PRIME-BOOST REGIMEN
WO2024052882A1 (en)	2022-09-09	2024-03-14	Access To Advanced Health Institute	Immunogenic vaccine composition incorporating a saponin
WO2024094881A1 (en)	2022-11-04	2024-05-10	Sanofi	Respiratory syncytial virus rna vaccination
WO2024110827A1 (en)	2022-11-21	2024-05-30	Pfizer Inc.	Methods for preparing conjugated capsular saccharide antigens and uses thereof
US20240181028A1 (en)	2022-11-22	2024-06-06	Pfizer Inc.	Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024116096A1 (en)	2022-12-01	2024-06-06	Pfizer Inc.	Pneumococcal conjugate vaccine formulations
WO2024121380A1 (en)	2022-12-08	2024-06-13	Pierre Fabre Medicament	Vaccinal composition and adjuvant
WO2024127215A2 (en)	2022-12-13	2024-06-20	Pfizer Inc.	Immunogenic compositions and methods for eliciting an immune response against clostridioides (clostridium) difficile
TW202438514A (zh)	2022-12-20	2024-10-01	法商賽諾菲公司	鼻病毒mrna疫苗
WO2024149832A1 (en)	2023-01-12	2024-07-18	Bavarian Nordic A/S	RECOMBINANT MODIFIED saRNA (VRP) FOR CANCER VACCINE
WO2024163327A1 (en)	2023-01-30	2024-08-08	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Epstein-barr virus glycoprotein 42 immunogens for vaccination and antibody discovery
WO2024166008A1 (en)	2023-02-10	2024-08-15	Pfizer Inc.	Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024180262A1 (en)	2023-03-02	2024-09-06	Sanofi	Compositions for use in treatment of chlamydia
WO2024186635A2 (en)	2023-03-03	2024-09-12	Celldex Therapeutics, Inc.	Anti-stem cell factor (scf) and anti-thymic stromal lymphopoietin (tslp) antibodies and bispecific constructs
WO2024201324A2 (en)	2023-03-30	2024-10-03	Pfizer Inc.	Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024214016A1 (en)	2023-04-14	2024-10-17	Pfizer Inc.	Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024224266A1 (en)	2023-04-24	2024-10-31	Pfizer Inc.	Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US20240374698A1 (en)	2023-05-05	2024-11-14	Sanofi	Compositions for use in treatment of acne
WO2024231565A1 (en)	2023-05-10	2024-11-14	Sanofi	Combination respiratory mrna vaccines
US20240398932A1 (en)	2023-05-11	2024-12-05	Sanofi Pasteur Inc.	Respiratory syncytial virus vaccine and methods of use
WO2024241172A2 (en)	2023-05-19	2024-11-28	Glaxosmithkline Biologicals Sa	Methods for eliciting an immune response to respiratory syncycial virus and streptococcus pneumoniae infection
WO2024246358A1 (en)	2023-06-01	2024-12-05	Sanofi	Thermostable compositions comprising mrna lipid nanoparticles
WO2025006737A1 (en)	2023-06-30	2025-01-02	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Genetically detoxified mutant of neisseria and outer membrane vesicle (omv) vaccine
WO2025017202A2 (en)	2023-07-19	2025-01-23	Sanofi	Porphyromonas gingivalis antigenic constructs
US20250090650A1 (en)	2023-09-06	2025-03-20	Sanofi	Modified influenza b hemagglutinin polypeptides and nucleic acids and uses thereof
WO2025057078A1 (en)	2023-09-14	2025-03-20	Pfizer Inc.	Adjuvanted immunogenic compositions comprising conjugated pneumococcal capsular saccharide antigens and uses thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2034118A1 (en) †	1970-07-09	1972-01-13	Seinfeld, Hugo, Brendel, Walter, Prof Dr . 8000 München	Xenogenic nucleic acids for enhancing antigenicity - of peptides and proteins
US4956296A (en) *	1987-06-19	1990-09-11	Genex Corporation	Cloned streptococcal genes encoding protein G and their use to construct recombinant microorganisms to produce protein G
US5059519A (en) *	1986-07-01	1991-10-22	University Of Massachusetts Medical School	Oligonucleotide probes for the determination of the proclivity for development of autoimmune diseases
CA1339596C (en)	1987-08-07	1997-12-23	New England Medical Center Hospitals, Inc.	Viral expression inhibitors
US5786189A (en) *	1989-11-29	1998-07-28	Smithkline Beecham Biologicals (S.A.)	Vaccine
US5248670A (en)	1990-02-26	1993-09-28	Isis Pharmaceuticals, Inc.	Antisense oligonucleotides for inhibiting herpesviruses
EP0468520A3 (en) *	1990-07-27	1992-07-01	Mitsui Toatsu Chemicals, Inc.	Immunostimulatory remedies containing palindromic dna sequences
JPH04352724A (ja) *	1990-07-27	1992-12-07	Mitsui Toatsu Chem Inc	免疫調節型治療剤
BR9106751A (pt)	1990-08-16	1993-08-17	Isis Pharmaceuticals Ind	Oligonucleotideo ou analogo de nucleotideo e processo para modulacao da atividade de uma infeccao por citomegalovirus
US5234811A (en) *	1991-09-27	1993-08-10	The Scripps Research Institute	Assay for a new gaucher disease mutation
EP0641353A4 (de) *	1991-11-18	1997-07-02	Tanox Biosystems Inc	Antisense-oligonukleotide für isotyp-spezifische unterdrückung der immunoglobinproduktion.
US5585479A (en) *	1992-07-24	1996-12-17	The United States Of America As Represented By The Secretary Of The Navy	Antisense oligonucleotides directed against human ELAM-I RNA
WO1994002471A1 (en)	1992-07-24	1994-02-03	Kumiai Chemical Industry Co., Ltd.	Triazole derivative, process for producing the same, pest control agent, and pest control method
CA2140542A1 (en) †	1992-07-27	1994-02-03	Abeysingle Padmapriya	Oligonucleotide alkylphosphonothioates
WO1994029461A1 (en) *	1993-06-11	1994-12-22	Commonwealth Scientific And Industrial Research Organisation	Method for specific silencing of genes by dna methylation
WO1995026204A1 (en) *	1994-03-25	1995-10-05	Isis Pharmaceuticals, Inc.	Immune stimulation by phosphorothioate oligonucleotide analogs
WO1996002555A1 (en) *	1994-07-15	1996-02-01	The University Of Iowa Research Foundation	Immunomodulatory oligonucleotides
US5629052A (en)	1995-02-15	1997-05-13	The Procter & Gamble Company	Method of applying a curable resin to a substrate for use in papermaking

1995
- 1995-02-07 WO PCT/US1995/001570 patent/WO1996002555A1/en active IP Right Grant
- 1995-02-07 EP EP01202814A patent/EP1167379A3/de not_active Ceased
- 1995-02-07 EP EP01202813A patent/EP1167378B1/de not_active Expired - Lifetime
- 1995-02-07 DK DK95911630.2T patent/DK0772619T4/da active
- 1995-02-07 CA CA002560114A patent/CA2560114A1/en not_active Abandoned
- 1995-02-07 PT PT95911630T patent/PT772619E/pt unknown
- 1995-02-07 EP EP95911630A patent/EP0772619B2/de not_active Expired - Lifetime
- 1995-02-07 AT AT95911630T patent/ATE328890T1/de active
- 1995-02-07 DE DE69535905T patent/DE69535905D1/de not_active Expired - Lifetime
- 1995-02-07 CA CA002194761A patent/CA2194761C/en not_active Expired - Lifetime
- 1995-02-07 EP EP01202811A patent/EP1167377B2/de not_active Expired - Lifetime
- 1995-02-07 US US08/386,063 patent/US6194388B1/en not_active Expired - Lifetime
- 1995-02-07 AT AT01202811T patent/ATE420171T1/de not_active IP Right Cessation
- 1995-02-07 ES ES01202811T patent/ES2320315T5/es not_active Expired - Lifetime
- 1995-02-07 ES ES95911630T patent/ES2267100T5/es not_active Expired - Lifetime
- 1995-02-07 AT AT01202813T patent/ATE509102T1/de not_active IP Right Cessation
- 1995-02-07 AU AU19127/95A patent/AU713040B2/en not_active Expired
- 1995-02-07 DE DE69535036T patent/DE69535036T3/de not_active Expired - Lifetime
- 1995-02-07 JP JP50499196A patent/JP3468773B2/ja not_active Expired - Lifetime
- 1995-02-07 ES ES01202813T patent/ES2366201T3/es not_active Expired - Lifetime
2002
- 2002-05-13 HK HK02103584.4A patent/HK1043598A1/zh unknown
- 2002-06-26 HK HK02104747.6A patent/HK1044950A1/zh not_active IP Right Cessation
- 2002-06-26 HK HK02104746.7A patent/HK1044949B/zh not_active IP Right Cessation
- 2002-10-16 JP JP2002302338A patent/JP2003144184A/ja not_active Withdrawn
2003
- 2003-06-23 JP JP2003178741A patent/JP4126252B2/ja not_active Expired - Lifetime
- 2003-06-23 JP JP2003178740A patent/JP2004024261A/ja not_active Withdrawn
2004
- 2004-03-11 JP JP2004069838A patent/JP2004215670A/ja not_active Withdrawn
2008
- 2008-01-25 JP JP2008015654A patent/JP2008169216A/ja not_active Withdrawn
2009
- 2009-03-10 JP JP2009057160A patent/JP2009148296A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
HK1043598A1 (zh)	2002-09-20
DK0772619T3 (da)	2006-10-09
US6194388B1 (en)	2001-02-27
EP1167377A3 (de)	2004-09-08
WO1996002555A1 (en)	1996-02-01
JP2004043466A (ja)	2004-02-12
CA2560114A1 (en)	1996-02-01
DE69535036D1 (de)	2006-07-20
ES2267100T3 (es)	2007-03-01
HK1044950A1 (zh)	2002-11-08
EP1167378B1 (de)	2011-05-11
DE69535036T2 (de)	2007-01-18
EP1167377A2 (de)	2002-01-02
ES2366201T3 (es)	2011-10-18
ATE328890T1 (de)	2006-06-15
JP3468773B2 (ja)	2003-11-17
ATE420171T1 (de)	2009-01-15
DE69535905D1 (de)	2009-02-26
CA2194761A1 (en)	1996-02-01
EP1167377B2 (de)	2012-08-08
DE69535036T3 (de)	2011-07-07
JP2003144184A (ja)	2003-05-20
EP0772619A1 (de)	1997-05-14
ES2320315T3 (es)	2009-05-21
HK1044949A1 (en)	2002-11-08
JP2004024261A (ja)	2004-01-29
EP1167377B1 (de)	2009-01-07
AU1912795A (en)	1996-02-16
PT772619E (pt)	2006-10-31
DK0772619T4 (da)	2011-02-21
JP2008169216A (ja)	2008-07-24
EP0772619B1 (de)	2006-06-07
JPH10506265A (ja)	1998-06-23
ES2267100T5 (es)	2011-04-08
EP1167379A3 (de)	2004-09-08
EP1167379A2 (de)	2002-01-02
HK1044949B (zh)	2012-01-27
JP4126252B2 (ja)	2008-07-30
ES2320315T5 (es)	2012-12-05
JP2009148296A (ja)	2009-07-09
CA2194761C (en)	2006-12-19
EP0772619B2 (de)	2010-12-08
AU713040B2 (en)	1999-11-18
EP1167378A3 (de)	2005-08-17
JP2004215670A (ja)	2004-08-05
EP1167378A2 (de)	2002-01-02

Publication	Publication Date	Title
DK0772619T4 (da)	2011-02-21	Immunmodulatoriske oligonukleotider
DE69727183D1 (de)	2004-02-19	Angetriebenes Handstück
ZA988789B (en)	2000-03-29	Vaccine.
DE69816696D1 (de)	2003-09-04	Pneumatisches chirurgisches Handstück
IT1292837B1 (it)	1999-02-11	Apparecchio chirurgico per biopsia.
ZA9711545B (en)	1998-06-24	Air treatment device.
HUP0004453A3 (en)	2004-05-28	Sterile drape
DZ2283A1 (fr)	2002-12-25	Composition de vaccin.
ZA973642B (en)	1997-11-25	DNA vaccine formulations.
ZA96722B (en)	1996-08-26	Combination therapy for hiv infection
FR2715304B1 (fr)	1996-04-26	Vaccin anti-allergique.
FI965196L (fi)	1996-12-23	HIV-infektion yhdistelmähoito
ZA9810445B (en)	1999-07-01	Novel bone surgical device.
ES1027473Y (es)	1995-02-16	Boton quirurgico de traccion ortodoncia.
ITBO930113V0 (it)	1993-05-19	supporto per strumenti odontoiatrici accessori.
ES1028663Y (es)	1995-07-01	Depresor lingual.
GB9610192D0 (en)	1996-07-24	DNA vaccine formulations
ES1025872Y (es)	1994-09-01	Maquina de traccion cervical.
ITMI942190A0 (it)	1994-10-26	Dispositivo di trattenimento del chiodo per martelli
ZA956662B (en)	1996-03-25	Combination therapy for HIV infection
ITMI981384A1 (it)	1999-12-18	Vaccino per hiv
DK199901724A (da)	2000-06-05	Blæserunderstøttet findesinfektionsapparat
ZA9710099B (en)	1998-07-29	Speculum device.
KR970058918U (ko)	1997-11-10	송풍기의 구동 장치
IT1285439B1 (it)	1998-06-08	Copriago di massima sicurezza per siringhe sterili

Legal Events

Date	Code	Title	Description
2011-11-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties